Express Pharma October 16-31, 2014

VOL. 9 NO. 24 PAGES 74

www.expresspharmaonline.com

Cover Story Ajit Singh: Pioneer of pharma packaging Market ‘DNA-based diagnostics present tremendous opportunities for us to invest’ Management Re-building Indian Pharma Inc 16-31 OCTOBER 2014,` 40

When excellence is your goal, partner with Ashland for world-class pharmaceutical technologies Ashland meets the needs of formulators by providing an unparalleled range of excipients and technologies, as well as longstanding polymer expertise and technical support from benchtop to commercialization for: • • • • •

Tablet film coating Tablet binding Tablet disintegration Controlled-release formulations Drug solubilization

® Registered trademark, Ashland or its subsidiaries, registered in various countries ™ Trademark, Ashland or its subsidiaries, registered in various countries * AquaSolve AS™ HPMCAD in the United Kingdom © 2013, Ashland AD-12529

Aquarius™ Preferred High-solids PVP/VA (HSP) film coatings systems • • • • •

Cellulosic- and copovidone-based coatings for solids up to 25% High tablet gloss and smoothness Shorter processing time Reduced water ingress into tablet cores Strong film adhesion

For more information, please contact your local Ashland Specialty Ingredients representative or visit us at ashland.com/aquarius.

CONTENTS MARKET Vol.9 No.24 OCTOBER 16-31, 2014 Chairman of the Board Viveck Goenka Editor Viveka Roychowdhury* Chief of Product Harit Mohanty BUREAUS Mumbai Sachin Jagdale, Usha Sharma, Raelene Kambli, Lakshmipriya Nair, Sanjiv Das

12

DNA-BASED DIAGNOSTICS PRESENT TREMENDOUS OPPORTUNITIES FOR US TO INVEST

14

GOI, PHARMA INDUSTRY JOINTLY FORM INDIA – RESPONSIBLE HEALTHCARE TRUST

15

STRIDES ARCOLAB TIES UP WITH SHASUN PHARMACEUTICALS

Bangalore Neelam M Kachhap Delhi Shalini Gupta DESIGN National Art Director Bivash Barua Deputy Art Director Surajit Patro Chief Designer Pravin Temble Senior Graphic Designer Rushikesh Konka

PM Modi's ‘Make in India’campaign highlights pharma as one of the keysectors for growth but it is essential to first rebuild Indian Pharma Inc’s reputation which has taken a hit in the last fewyears | P26

Senior Artist Rakesh Sharma Photo Editor Sandeep Patil MARKETING Regional Heads Prabhas Jha - North Dr Raghu Pillai - South Sanghamitra Kumar - East Harit Mohanty - West Marketing Team Rajesh Bhatkal GM Khaja Ali Ambuj Kumar E Mujahid Yuvaraj Murali Ajanta Sengupta PRODUCTION General Manager B R Tipnis

P35: CLINICAL UPDATE

MANAGEMENT

Novartis’ Gilenya reduces brain shrinkage matters for people with MS

PHARMA ALLY

38

IKA LAUNCHES MOBILE APPLICATION LABORATORY VAN

39

SIGNET TIES-UP WITH 3V SIGMA SPA

P38: VENDOR NEWS IDT Biologika sets up new multipurpose biologics and vaccines facility 38

P68: AWARD Glenmark bags Civic Award 2013-14

Manager Bhadresh Valia Scheduling & Coordination Rohan Thakkar

P68: CAMPUS BEAT

CIRCULATION Circulation Team Mohan Varadkar

HK College of Pharmacy celebrates 6th Scientific Day

33

‘IRHT WOULD FOCUS ON AFRICA, JAPAN AND LATIN AMERICA AS POTENTIAL MARKETS OF THE FUTURE’

Express Pharma Reg. No.MH/MR/SOUTH-77/2013-15, RNI Regn. No.MAHENG/2005/21398. Printed for the proprietors, The Indian Express Limited by Ms. Vaidehi Thakar at The Indian Express Press, Plot No. EL-208, TTC Industrial Area, Mahape, Navi Mumbai - 400710 and Published from Express Towers, 2nd Floor, Nariman Point, Mumbai - 400021. (Editorial & Administrative Offices: Express Towers, 1st Floor, Nariman Point, Mumbai - 400021) *Responsible for selection of news under the PRB Act. Copyright @ 2011. The Indian Express Ltd. All rights reserved throughout the world.

Reproduction in any manner, electronic or otherwise, in whole or in part, without prior written permission is prohibited.

EDITOR’S NOTE

Playing the frenemy card

T

he pricing pill looks set to choke pharmaceutical companies in India again. On October 9, barely a fortnight after the National Pharmaceutical Pricing Authority (NPPA) withdrew its now infamous ‘internal guidelines’, a Spicy IP blogpost reported that the All India Drug Action Network (AIDAN) had filed yet another PIL in the Delhi High Court.

The AIDAN’s PIL alleges that the NPPA’s volte face was a result of ‘browbeating’ by the Secretary, Department of Pharmaceuticals (DoP). The PIL reportedly refers to internal memos where the DoP has sent an endorsed copy of its opinion on the guidelines and directed the NPPA to withdraw them.

AIDAN alleges that this amounts to ‘sabotaging the efforts of the Union Government and the stand taken by the Union Government in their two affidavits’ at ‘huge financial benefits to the pharmaceutical industries.’

Will the AIDAN’s argument, that the NPPA is an independent body, and cannot be dictated to by the central government, prevail? The Spicy IP blog post comments that apart from its consequences for pharma companies and patients, the petition throws up interesting and important Constitutional and Administrative law questions.

But organisations like the AIDAN are not alone in questioning the escalating prices of medicines. On October 2, Senator Bernie Sanders (who is also the chairman of a US Senate health care subcommittee) and US Rep Elijah Cummings (a ranking member of the US House oversight committee) announced that they have written letters to 14 pharma companies, asking them to explain why there are “huge upswings in generic drug prices that are hurting (US) patients.” Prominent Indian companies like Dr Reddy’s Laboratories, Sun Pharmaceutical Industries, and Zydus Pharmaceuticals (US) as well as the likes of Actavis, Mylan and Teva are some of the 14 companies who have been sent such letters.

How will big generic pharma respond to these letters? Most probably by going on the offensive and questioning the data. Commenting on the SandersCummings report and its impact on the global generics industry, Bhavik Narsana, Partner, and Sameer Sah, Principal Associate, Khaitan & Co say that if the data is accurate, there is definitely a cause for concern. They are not surprised that a US congressional investigation was initiated given the Obama administration’s healthcare reform agenda.

But they stress that it remains to be seen whether

10

EXPRESS PHARMA

October 16-31, 2014

The Gilead- Sovaldi deal signals that innovator and generic companies are now firm frenemies: friendly enemies who are increasingly open to collaborate for mutual benefit.But will these partnerships result in the ‘greater common good’?

the data is indeed reliable. They caution that if the (US) government does take some remedial action, it is bound to hit manufacturers’ toplines as the US is an important market for generics manufacturers, including Indian exporters.

Sanders’ and Cummings’ letters were followed by a hard hitting report on CBS’ 60 Minutes, aired on October 5, questioning the rationale for increasing prices of cancer drugs. Keeping the drug price issue on the boil is an easy task for the media, patient groups and politicians but this pressure seems to be one of the reasons why some pharma companies are re-thinking pricing strategies. The most recent example could be Gilead Sciences’ decision, to license seven Indian generic drug companies to make and sell Sovaldi at a lower cost. Though critics say this is just a smart way to negate competition, and avoid patent challenges from these generic companies, the deal signals that innovator and generic companies are now firm frenemies: friendly enemies who are increasingly open to collaborate for mutual benefit.

But will such partnerships result in the ‘greater common good’? The Government of India and regulatory bodies like the NPPA will have to increase their vigilance to prevent monopoly-like situations in the market. The Sanders-Cummings report has to be seen in the same light but governments/regulators also have to find a way to reward companies who invest in R&D. Unfortunately, when politicians get involved, the public backlash forces regulators to swing to the other extreme, as we have seen in the case of the amended clinical trial regulations.

On the IPR front, Prime Minister Modi has managed to hold the line during his US trip. He has agreed to form a high level working group on IP where both the US and Indian sides will present their interpretations of the sticky points. This should not be seen as a capitulation but an engagement. It appears that he is intent on following the pre poll manifesto of his party, the BJP, which mentions that the country should “embark on the path of IPRs and patents in a big way” and “establish an Intellectual Property Rights Regime which maximises the incentive for generation and protection of intellectual property for all type of inventors.” Seems like PM Modi too is playing the frenemy card: keep your friends close, but your frenemies even closer!

VIVEKA ROYCHOWDHURY Editor viveka.r@expressindia.com

MARKET I N T E R V I E W

DNA-based diagnostics present tremendous opportunities for us to invest VC firms are integral to a thriving ecosystem, for both entrepreneurship and new start-ups in new emerging areas of the future. Bobba Venkatadri, General Partner, Ventureast discusses this and more in an interview with Shalini Gupta

What are some of trends you see in the lifesciences and biotechnology space as a venture capitalist?

We are in the middle of a biomedical revolution which in my view is more profound and far reaching than the industrial and digital revolutions that we have seen. The DNA was discovered in the late 70s and the birth of Genentech, Amgen and such companies happened in the 80s. Now a third of the new drugs approved by the US FDA are for large molecules which address complex diseases.

Genomics, MRI, stem cells and bioinformatics are offering new possibilities that not only heal but predict and prevent. Doctors may do a genetic test for certain diseases which helps detect and diagnose a disease earlier such as cancer.

Biomarkers are replacing biopsies for detecting tumours, treatments are designed for particular genetic defects, the world is moving to personalised diagnostics and genetic biomarkers. Big data is another trend with electronic hospital records giving us insight into how and why patients taking the same class of drug show different outcomes. The mining of data has revealed that a drug which is used as an antidepressant could also have a side effect of killing tumour cells. This discovery enabled

12

EXPRESS PHARMA

October 16-31, 2014

a company here in Bay Area to get into human clinical trials in one tenth of the time it takes to get into human clinical trials normally and at a fraction of the cost.

Where does India stand on the investment map? What potential do you see?

From a venture capital perspective, in the last ten years, percentage of medicines consumed by emerging countries such as China, Brazil, Russia has gone up significantly. This number has risen from 10-15 per cent to 20 per cent in 2011. The total pharma market is estimated to be $1.2 trillion in 2016. In 2011, the US accounted for 50 per cent of the sales, with the US, Japan and the UK together making 80 per cent of the market, now they make 50 per cent combined, as the emerging countries comprise 30 per cent. Our market share is increasing because of improvement in economies. Total per capita consumption of drugs in India is $33 and the lowest is BRIC countries, with $180 in Brazil, $333 in Indonesia and the US at $800. Indian pharma market is growing 15-20 per cent whereas the US and Europe are growing barely at two to three per cent. That also tells you why large companies are getting into India. M&As have been an expansion tool for companies such as Abbott.

From a venture capital perspective, in the last ten years, percentage of medicines consumed by emerging countries such as China, Brazil, Russia has gone up significantly

These deals either help get market access or product access, geographic expansion in emerging markets or can be mega deals such as Pfizer acquiring Abbott.

Interestingly, 60 per cent of M&As add value and 40 per cent of them destroy value.

From 2010-2013, pharma index has gone up 60 per cent and biotech index has gone up 113 per cent. Those investing in biotech companies in the advanced world are making more money than those investing in pharma companies. There is also a big blur between traditional big pharma and biotech companies, both in the US and India, as companies realise the importance of innovation and large molecules.

How is the VC ecosystem in India?

From a VC perspective, it is a very difficult route to get to an IPO and access capital, unlike China. As a VC, when we invest money in a company, IPO is not the easiest exit, so we have to look for strategic exits, PE guys buying them out. The ecosystem includes the science at the university level, and the skill level of graduate and PhD students.

However, we have to admit that we don't have world class scientists and nobel laureates yet. In the basic breakthrough sciences we're not there yet compared to

the US, Europe or Japan where all innovation is still taking place. Then there is a skill gap between the graduates passing out and what the industry expects out of them. One of the key ecosystem component is industry, government and academia working together and we have long way to go there. TDB and DBT are doing things, but there's bureaucracy still. The ecosystem still needs a lot of improvement.

What are the investment opportunities of the future?

Biosimilars, biobetters, vaccines, and DNA-based diagnostics present tremendous opportunities for us to invest. Injectable drugs is one of the hottest areas, tablets and capsules, low barrier entries are what we're looking at. We invested in Gland Pharma, back in 90s and have invested in Evolva (genetic chemistry), and Bioserve (DNA sequencing company) based in Hyderabad and the US that got acquired by Cancer Genetics Inc. In Bangalore, we have invested in Richcore which makes recombinant enzymes, and Biocon.

Besides this, we have also invested in a couple of device companies in the US into cardiology and oncology.

It is going to take India a while to get good in discovery sciences. We should licence

discovery from wherever we get it, be it Japan, the US or Europe. The government needs to be the change agents to increase cooperation between themselves, academia and industry. The focus needs to be on improving labs, quality of training, Masters and PhD programmes. Within that the specific opportunities for investment are specialty pharma.

How do you invest in a company?

We get a number of business proposals. A few questions that we ask are: Is the area large enough or a

The government needs to be the change agents to increase cooperation between themselves, academia and industry. The focus needs to be on improving labs, quality of training, Masters and PhD programmes nice focus area? Does the company have a track record? Are they bringing something new to the table?

How does this differentiate?

For example, we invested in Portea Medical, which is breaking new frontiers of homecare. We are also investing in a saliva-based point of care test in the US

EXPRESS PHARMA

13

October 16-31, 2014

for diabetes. We look at the technologies which differentiates the companies and it is judgemental, there' no magic formula. At the end, it is human judgement.

Biosimilars present the next opportunity ten years hence despite challenging

times. Your comments.

The problem is that it is very expensive to develop a biosimilar, it is not like a generic chemistry molecule, from phase I to phase II and then getting them into markets such as the US and Europe. Companies like Doctor Reddy’s Labs

developed the molecules and marketed them in the emerging world, as they couldn't afford to fund clinical development they teamed up with Merck KGaA. It is a very good example for India, where we need to establish production capacity, develop the technology using

expression systems or cell lines from the US and concentrate on what we do best- process development. A lot of Indian companies put blinders on emerging trends in expression systems and want to do it on their own, instead of collaborating. shalini.g@expressindia.com

MARKET COMPANY WATCH

GoI,pharma industry jointly form India – Responsible Healthcare Trust To give more thrust to the Brand India Pharma campaign GOVERNMENT OF India (GoI) and the major pharmaceutical industry organisations have come together to form the India – Responsible Healthcare Trust to power the Brand India Pharma campaign. A one-of-its-kind public-private partnership, the formation of the Trust represents the commitment to both drive and safeguard the interests of the Indian pharma industry.

The Trust chaired by the Commerce Secretary comprises key stakeholders, namely, the Indian Pharmaceutical Alliance (IPA), Indian Drug Manufacturers’ Association (IDMA), Bulk Drug Manufacturers Association (BDMA), Association of Biotechnology Led Enterprises (ABLE), Pharmaceutical Export Promotion Council of India (Pharmexcil) and In-

The India – Responsible Healthcare Trust is expected to take the Brand India Pharma campaign to the next level.

The primary objective of this Trust will be to position India as a Responsible Healthcare provider dia Brand Equity Foundation (IBEF). The Trust aims to combine both financial and non-financial resources towards a common agenda. The Trust aims to create better awareness and develop an informed perspective about Brand India Pharma in both the domestic and global mar-

kets.

“The India – Responsible Healthcare Trust will spearhead the Brand India Pharma initiative through the second phase. The industry-government partnership is an important milestone in the campaign,” said Rajeev Kher, Commerce Secretary, Govern-

matic disorders. It is 30 per cent more effective than conventional products, as proven by a series of toxicity and safety studies. It has 150 per cent enhanced retention for longer effect, improved relief and better mobility,” said Dr Manu Chaudhary, Joint Managing Director and Director, Research, Venus Remedies.

RANBAXY LABORATORIES has launched ABSORICA (isotretinoin) 25 mg and 35 mg capsules into the US healthcare market. ABSORICA has become the most prescribed branded oral isotretinoin in the US, as per a recent independent survey conducted with dermatologists.

The product is licensed by Ranbaxy from Cipher Pharmaceuticals. It is indicated for the treatment of severe recalcitrant nodular acne in patients 12 years of age and older.

Due to its high lipophilicity, oral absorption of isotretinoin is enhanced when given with a high-fat meal, however, ABSORICA, which is formulated using patented Lidose technology, can be given without regards to meals. The fasted AUC0-t of ABSORICA is approximately 83 per cent greater than that of Accutane, while both products are bio-equivalent under fed conditions. ABSORICA is therefore not interchangeable and not substitutable with generic products of Accutane.

Dr Ashish Anvekar, Vice President of Brand Division North America, Ranbaxy, said, “Since isotretinoin dosing is weight-based, we are pleased to make available these valuable, additional dosing options exclusively for ABSORICA. This will give prescribers the enhanced flexibility, to tailor the isotretinoin therapy depending on the patient’s weight, and benefit the group of patients who are in that weight range, irrespective of their dietary intake. Ranbaxy continuously seeks to innovate and bring value based options to the speciality of dermatology and patients.”

EP News Bureau- Mumbai

EP News Bureau- Mumbai

ment of India.

The Brand India Pharma campaign was launched under the aegis of the Department of Commerce at CPhI Japan in March 2012. The Brand India Pharma showcase has made its presence felt at prestigious events like CPhI Worldwide consistently over the past two years. The Department of Commerce along with IBEF and Pharmexcil has invested huge resources with measurable and impacting results in the first phase of the Brand India Pharma campaign.

The India – Responsible Healthcare Trust is expected to take the Brand India Pharma campaign to the next level. The primary objective of this Trust will be to position India as a Responsible Healthcare provider.

EP News Bureau- Mumbai

Venus forays into Singapore’s topical pain management market Gets marketing authorisation and patent for its pain reliever Trois VENUS REMEDIES has entered Singapore’s topical pain management market with a marketing authorisation and patent for its herbal nanotechnology-based pain reliever Trois. The company is holding talks with various pharmaceutical firms for tieups to market Trois in Singapore.

A product for topical use, Trois provides quick and last-

14

EXPRESS PHARMA

October 16-31, 2014

ing relief to patients suffering from rheumatic disorders, low back pain, osteoarthritis, rheumatoid arthritis, gout, knee pain, ankylosing spondylitis, fibromyalgia and pain originating from muscles and tendons. Currently, more than 1.5 billion people worldwide suffer from chronic pains of varying degree. The company has filed the product, process and use patent

for Trois in 46 countries.

Pawan Chaudhary, Chairman and Managing Director said, “This is a great opportunity for us to capture a sizeable share in this segment of the Singapore pharma market. Trois has a huge potential in Singapore.”

“Trois is the safest known topical product for management of pain and inflammation associated with rheu-

Ranbaxy launches ABSORICA in the US

MARKET

Strides Arcolab ties up with Shasun Pharmaceuticals Creates vertically integrated pharma company with multiple revenue streams THE BOARD of Directors of Strides Arcolab and Shasun Pharmaceuticals have approved a scheme of amalgamation between the two companies. The combination creates a vertically integrated pharmaceutical company of scale with strong presence in front-ended regulated markets finished dosages, emerging markets branded generics, institutional business, active pharmaceutical ingredients and contract research and manufacturing services.

The combination will significantly enhance finished dosages portfolio in niche and complex domains with a pipeline of over 100 products and accelerates product filings

with a combined R&D strength of over 400 personnel. It will significantly de-risk its operations with the combined entity having 12 manufacturing facilities including three US FDA approved finished dosage manufacturing facilities, two US FDA approved API manufacturing facilities, one US FDA approved CRAMS facility and six manufacturing facilities catering to the emerging markets.

The merged entity will leverage Shasun’s best in class API manufacturing capacities and shift focus towards niche API’s aligned with finished dosages portfolio and pipeline. It will significantly synergy opportunities in operations and cost sav-

The merged entity will leverage Shasun’s best in class API manufacturing capacities and shift focus towards niche API’s aligned with finished dosages portfolio and pipeline ings through economies of scale. The amalgamation will create a top 15-listed Indian pharma company by revenue with increased scale and visibility to drive future growth of the group.

Arun Kumar, Founder and Group Chief Executive Officer,

Strides stated, “Since the divestment of our injectables business, which resulted in significant value creation for our shareholders, Strides has refocused on its oral finished formulation business. Today’s proposed combination with Shasun accelerates our strategy and

growth prospects by creating a larger scale, fully integrated, leading Indian pharma company with multiple growth drivers and synergies that will allow for enhanced profitability and more efficient use of our combined infrastructure and enhanced value creation opportunities for the combined shareholder group.”

Abhaya Kumar, Chief Executive Officer and Managing Director, Shasun stated, “Strides and Shasun bring complementary strengths and shared values of developing products and market opportunities across geographies and the combination accelerates both scale and scope.”

EP News Bureau- Mumbai

The Standard of Comparison

Pharmaceutical Grade Crystalline, Spray Dried, Anhydrous, and Inhalation Lactose • For more than 70 years, we have delivered the industry's most extensive Lactose portfolio

www.SheffieldBioScience.com

• The original patent for Anhydrous Direct Tabletting (DT) Lactose • Batch to Batch Consistency • Global technical service, regulatory and application expertise to ensure regional and global market compliance

To subscribe: bpd.subscription@expressindia.com

Registered Office Address: 17th Floor, Nirmal Building, Nariman Point, Mumbai - 400021 Corporate Identification Number: U15400MH2010PTC202946 Tel.: +91 22 27815003, Fax Number ; (022- 27815989) Email: Kerry-India.Info@kerry.com

EXPRESS PHARMA

15

October 16-31, 2014

MARKET

Decreasing herb production could hamper Ayurveda industry Shortages, fears of dilution could prevent industry tapping increasing demand

Steena Joy Kochi THE AYURVEDA industry is facing problems on the production front, which if not sorted out immediately, could impact the long-term growth prospects of the industry.

Alerting the industry to some of these problems Dr GG Gangadharan, Medical Director, Institute of Ayurveda and Integrative Medicine (I-AIM) Healthcare Centre and Chairman, National Steering Committee for Global Ayurveda Festival, (a biennial get together of the Ayurveda fraternity from the world over), said, "On the one hand, mass production of Ayurvedic medi-

cines is diluting the science. On the other, a shortage of herbs required to produce these medicines is looming. When the demand for Ayurveda increases, how will the treatment centres get the plants and herbs needed for production?

Ayurveda uses some 1600 plants and herbs of which only 120 are in actual usage. Of these about 60 are not easily available.”

Alluding to the potential of the industry, Gangadharan said,“The global wellness market is worth some $five trillion.

India earns ` 9,000 crore from Ayurveda services alone and we have not even seen the tip of the iceberg as far as this science is concerned. Ayurveda is

The global wellness market is worth some $five trillion.

India earns ` 9,000 crore from Ayurveda services alone

To invest about $36.65 million over three years on areas including machinery and equipment for the facility

16

EXPRESS PHARMA

October 16-31, 2014

United States and European Union over Tehran's nuclear programme, allows trade in humanitarian goods such as food and medicine, not many Indian drugmakers have significant presence in Iran.

"Cipla has been providing medicines to patients in Iran for several years and believes that Iranian patients cannot be denied to medicines due to sanctions," the company said in a statement to Reuters.

"We have observed a high prevalence of respiratory disorders and cancer cases in

herbs like gugulu which is the most used in Ayurveda is difficult to cultivate. So the government has to subsidise farmers and have a buyback arrangement.”

Baby Mathew, Chairman and Managing Director, Somatheeram Ayurveda Group, opined, “It is good that the government has implemented GMP in Ayurvedic medicine manufacturing. But sadly, there are no high standard research facilities for Ayurveda like the IITs for technology.

The government has finally given approval for setting up an Ayurveda University, so at least the health department are on the right track. steena.joy@expressindia.com

Novartis announces change in Executive Committee

Cipla to set up a manufacturing unit in Iran CIPLA HAS agreed to set up a manufacturing plant in Iran, as part of its strategy to boost its presence in the country's $4 billion pharmaceuticals market that is growing at about 13 per cent annually.

Cipla, which will own 75 per cent stake in the plant being set up in partnership with its local distributor, will invest about $36.65 million over three years on areas including machinery and equipment for the facility.

Although the sanctions regime, imposed by the

the only area where India is 5,000 years ahead of other countries. But this success story is in danger. Now even other countries like Switzerland, and Sri Lanka our neighbour are offering Ayurveda. As Ayurveda is not officially recognised by many countries, it is difficult for patients travelling to India for Ayurveda to get medical insurance.”

Gangadharan felt that a strong backward integration model needs to be adopted.

“We have urged the government to implement a nursery technology programme to step up cultivation. Here again, some plants need to be cultivated 'in situ' in their original environment or they will lose their medicinal value. Some

Iran. There were also patients suffering with diseases like thalassemia, HIV/AIDS and heart diseases, who have been at a risk due to the impact of sanctions," it said.

Setting up the plant will help in faster registrations of new products and will improve its competitive position, the company said, adding it does not expect any impact on its US and European businesses due to its investments in Iran.

Reuters

NOVARTIS CONFIRMED that following completion of the transactions with GlaxoSmithKline (GSK) and Eli Lilly and Company (Lilly) in the coming months, the three business leaders of the Novartis divisions at the centre of the transaction will leave the Executive Committee of Novartis (ECN). The expected changes to the ECN are subject to the closing of the transactions announced on April 22, 2014. Novartis expects the transaction with GSK to be completed in the first half of 2015, and the transaction with Eli Lilly for its animal health business to close in the first quarter of 2015.

George Gunn, currently Division Head, Novartis Animal

Health, will reach his contractual retirement age in July 2015 and will retire from Novartis. Upon closing of the animal health transaction with Lilly he will leave the ECN. Brian McNamara, currently Division Head, Novartis OTC, will transition to GSK as Head of Americas and Europe for the consumer health businesses, reporting to the President of GSK Consumer Healthcare, effective at closing of the transaction. Andrin Oswald, currently Division Head, Novartis Vaccines, will be leaving Novartis to pursue other opportunities following closing of the transaction with GSK. EP News Bureau- Mumbai

MARKET

Strides Arcolab,GMS Holdings agreement Announces strategic investor for its greenfield biotech project STRIDES ARCOLAB has entered into an agreement with GMS Holdings whereby GMS will invest $29.10 million for a 25.1 per cent stake in Stelis Biopharma, the biotech arm of Strides Arcolab, to fund its greenfield project. The transaction is expected to close in Q4 of 2014 and is subject to customary closing conditions, regulatory and corporate approvals, as may be required.

Joe Thomas, Chief Corporate Development Officer, Strides and Head – Biotech division stated, “We are pleased

The transaction is expected to close in Q4 of 2014 and is subject to customary closing conditions, regulatory and corporate approvals, as may be required

to have GMS Holdings as our strategic partner for the emerging Biotech business.

GMS Holdings has a track record of having partnered in successful businesses, with a strong presence in the MENA region.”

Ghiath Sukhtian, Chairman, GMS Holdings stated, “We are delighted to be partnering with Strides on this ex-

EXPRESS PHARMA

17

October 16-31, 2014

citing venture. Strides has a long track record of building

successful pharma platforms and we believe that by joining

our efforts on this investment we can create significant

value for both our groups.”

EP News Bureau- Mumbai

MARKET

Merck Serono to collaborate with The Institute of Cancer Research,London and Wellcome Trust To co-develop anti-cancer drugs MERCK SERONO, the biopharmaceutical division of Merck, The Institute of Cancer Research (ICR), and the Wellcome Trust, London, announced a co-development and license agreement building on two independent research programmes at both the ICR and Merck Serono to identify inhibitors of tankyrase, an enzyme of the poly (ADP-ribose) polymerase family.

The collaboration will be jointly funded by Merck Serono and the Wellcome Trust. The existing drug discovery programme at the ICR is supported by a Wellcome Trust Seeding Drug Discovery Award. In a joint effort, a team led by Dr Chris Lord and Professor Alan Ashworth at the ICR and a research group at Merck Serono will aim to progress chemical compounds that have emerged from both organizations’ tankyrase inhibitor programmes towards

clinical development. At the end of the collaboration period, Merck Serono will take over full responsibility for the selected clinical development candidate, with the goal of bringing a new cancer therapeutic drug to patients.

Lord, Team Leader in the Division of Breast Cancer Research at The Institute of Cancer Research, London, said, “Tankyrase inhibitors provide a unique opportunity to target one of the most common characteristics of cancer cells - their dependency on the so-called ‘Wnt signaling’ pathway. Both Merck Serono and the group at the ICR have already made notable progress in developing tankyrase inhibitors. Working with Merck Serono will allow us to jointly accelerate our programme with the aim to ultimately make tankyrase inhibitors available to cancer patients.”

“We are delighted to work together with Dr Chris Lord

The collaboration will be jointly funded by Merck Serono and the Wellcome Trust. The existing drug discovery programme at the ICR is supported by a Wellcome Trust Seeding Drug Discovery Award and Professor Alan Ashworth.

With this partnership, we aim to harness the already well advanced tankyrase programmes at both ICR and Merck Serono and hope to ultimately translate these in to novel treatment options for cancer patients. We will build on a joint compound base of potent tankyrase inhibitors and will leverage both sites’ scientific knowledge about the ‘Wnt pathway’ that plays a major role in signal transduction

for tumor growth”, said Dr Andree Blaukat, Head of the Translational Innovation Platform Oncology at Merck Serono. “The interest of the Wellcome Trust shows its belief in our researchers’ scientific data. It also shows the importance of cademia-industry collaboration models in pharmaceutical development to progress the most promising investigational compounds into clinics with the aim of bringing them to patients.”

“This agreement highlights the importance of translational funding, such as the awards provided under the Seeding Drug Discovery scheme, to reduce the risk of drug discovery programmes so that they become attractive to partners who have the ability to bring a product to market”, said Dr Ted Bianco, Director of Innovations at the Wellcome Trust.

Some of the most promising advances in cancer research have been small-molecule inhibitors which block the activity of members of the poly (ADP-ribose) polymerase (PARP) enzyme family, which includes the enzyme tankyrase.1

References 1. JL Riffell et al, Tankyrase-targeted therapeutics: expanding opportunities in the PARP family.

Nat Rev Drug Discov. 2012 Dec;11(12):923-36. doi: 10.1038/nrd3868 EP News Bureau- Mumbai

CONTRIBUTOR’S CHECKLIST ❒ Express Pharma accepts editorial material for

❒ We welcome information on new products and

regular columns and from pre-approved contributors / columnists. ❒ Express Pharma has a strict non-tolerance policy of plagiarism and will blacklist all authors found to have used/refered to previously published material in any form, without giving due credit in the industryaccepted format. All authors have to declare that the article/column is an original piece of work and if not, they will bear the onus of taking permission for re-publishing in Express Pharma. ❒ Express Pharma's prime audience is senior management and pharma professionals in the industry. Editorial material addressing this audience would be given preference. ❒ The articles should cover technology and policy trends and business related discussions. ❒ Articles for columns should talk about concepts or trends without being too company or product specific. ❒ Article length for regular columns: Between 1200 1500 words. These should be accompanied by diagrams, illustrations, tables and photographs, wherever relevant.

services introduced by your organisation for our various sections: Pharma Ally (News, Products, Value Add), Pharma Packaging and Pharma Technology Review sections. Related photographs and brochures must accompany the information. ❒ Besides the regular columns, each issue will have a special focus on a specific topic of relevance to the Indian market. ❒ In e-mail communications, avoid large document attachments (above 1MB) as far as possible. ❒ Articles may be edited for brevity, style, and relevance. ❒ Do specify name, designation, company name, department and e-mail address for feedback, in the article. ❒ We encourage authors to send their photograph.

Preferably in colour, postcard size and with a good contrast.

18

EXPRESS PHARMA

October 16-31, 2014

Email your contribution to: The Editor, Express Pharma, Business Publications Division,

The Indian Express Limited, 1st Floor, Express Towers, Nariman Point, Mumbai - 400 021.

Tel: 91-22-2202 2627 / 2285 1964/ 6744 0000 Fax: 91-22-2288 5831 editorial.ep@expressindia.com

MARKET

Sun Pharma and Merck in agreement Sun Pharma will acquire worldwide rights to tildrakizumab for use in all human indications from Merck in exchange for an upfront payment of $80 million MERCK & CO, known as MSD outside the US and Canada, and Sun Pharmaceutical Industries through their respective subsidiaries, entered into an exclusive worldwide licensing agreement for Merck’s investigational therapeutic antibody candidate, tildrakizumab, (MK-3222), which is currently being evaluated in phase III registration trials for the treatment of chronic plaque psoriasis, a skin ailment.

Under terms of the agreement, Sun Pharma will acquire worldwide rights to tildrakizumab for use in all human indications from Merck in exchange for an upfront payment of $80 million. Merck will continue all clinical development and regulatory activities, which will be funded by Sun Pharma. Upon product approval, Sun Pharma will be responsible for regulatory activities, including subsequent submissions, pharmacovigilance, post approval studies, manufacturing and commercialisation of the approved product. Merck is eligible to receive undisclosed payments associated with regulatory (including product approval) and sales milestones, as well as tiered royalties ranging from mid-single digit through teen percentage rates on sales.

“Consistent with our previously announced global initiative to sharpen our commercial and R&D focus, including prioritising our late stage pipeline candidates, we are pleased to enter into this agreement with Sun Pharma to help realise the potential of tildrakizumab for patients with chronic plaque psoriasis,” said Iain D Dukes, Senior vice president, Business Development and Licensing, Merck Research Laboratories.

"Sun Pharma is pleased to enter into this collaboration with Merck, a recognised

EXPRESS PHARMA

19

October 16-31, 2014

leader in the field of inflammatory/immunology therapies,

for this late-stage candidate for chronic plaque psoriasis,” said

Kirti Ganorkar, Senior Vice President, Business Develop-

ment, Sun Pharma. ” EP News Bureau- Mumbai

FULL ATTENTION TO THE TINIEST DETAIL. A big machine with some great details.

The CP400 marks a milestone in packaging technology: in 1993 it was the world’s first machine in which the classic vertical shaft was replaced by servo-motor drive of all functional units. After some 20 years of ongoing development, the CP400 has reached a unique degree of maturity; its exemplary GMP design guarantees maximum production security.

For further info please contact our local partner: www.salesworthsynergies.com or check www.mediseal.de

MARKET POST EVENT

AWACS felicitates pharma achievers The awards were divided in three categories AWACS AWARDS in Marketing Excellence 2014 took place recently at the Nehru Centre Auditorium in Mumbai in the presence of pharma bigwigs from across India. It was the first edition of these awards.

AWACS is a market research agency with syndicated audit Pharma Trac. These awards are instituted to recognise and reward top performers of the domestic pharma industry.

The AWACS awards were divided in three categories, namely, top 20, companies ranked between 21-50 and

20 EXPRESS PHARMA October 16-31, 2014

above 50.

The last financial year was one of the most challenging in recent times, however, certain brands have shown remarkable volume growth post getting a huge top line hit due to DPCO. For such products AWACS created a special category on best DPCO revival. They were classified by company size, and under acute and chronic categories, as well as under specialty brand.

Ameesh Masurekar, Director, AWACS, said, “There are a lot of people in the industry

The awards are instituted to recognise and reward top performers of the domestic pharma industry

that are working hard but do not get individual credit. These awards will help to achieve this.”

Ganesh Nayak, Chief Operating Officer and Executive Director, Zydus Cadila, said, “AWACS has added a lot of value in terms of business intelligence to sharpen our strategies. AWACS Pharma Trac has created a competition which has in turn helped us in getting better services.”

He added that the pharma industry earlier didn’t have a platform which recognised the

top performers. He suggested, “AWACS should institutionalise these awards in such a way that every year we will look forward for it.”

Dr Tarun Gupta, Professor Emeritus at School of Business Management and Chairman, MBA - Pharmaceutical Management School of Business Management SVKM’s NMIMS was conferred with the Lifetime Achievement award for his exemplary contribution towards the pharma industry.

EP News Bureau

EVENT BRIEF NOVEMBER 2014 - MAY 2015 3

Multicentre International Data Integrity Workshop

MULTICENTRE INTERNATIONAL DATA INTEGRITYWORKSHOP Date: November 3-4, 2014 Venue: New Delhi Date: November 6-7, 2014 Venue: Mumbai Date: November 10-11, 2014 Venue: Hyderabad Date: November 13-14, 2014 Venue: Bangalore Summary: Members of the US Food and Drug Administration along with other international regulatory agencies such as the European Directorate for the Quality of Medicines & Healthcare (EDMQ) and others will be hosting a two-day workshop. It will provide an opportunity to build awareness for regulatory agencies and industry regard-

ing the importance of integrity in pharmaceutical science.

The workshop will include focused discussions related to trends concerning data integrity, and the exploration of potential solutions.

Contact details: Manoj Trivedi Sr Manager (Mktg & Program Development) DIA (India) Mob: +91 9819777493 Email: Manoj.Trivedi @diaindia.org

ASIA PHARMA EXPO-2015 Date: January 8-10, 2015 Venue: Bangabandhu International Conference Centre, Dhaka, Bangladesh

To subscribe: bpd.subscription@expressindia.com

8

Asia Pharma Expo-2015 Summary: Bangladesh Association of Pharmaceutical Industries will host international exhibition on South Asian Pharmaceutical industry, Asia Pharma Expo-2015. The exhibiting companies from more than 26 countries across the world are expected to participate.

The expo will be accommodating 400 booths to the exhibitors. Major OEM suppliers from Asia, Europe and the US are likely to participate.

Contact details: Tel: +91 7940008233/ 53 Mob: +91 8000481114 Email: ceo@GPEexpo.com Website: www.asiapharma.org

13

PHARMA Pro & Pack Expo 2015

PHARMA PRO & PACK EXPO 2015 Date: May 13-15, 2015 Venue: Mumbai Exhibition Centre, Mumbai Summary: PHARMA Pro & Pack Expo 2015 will be organised by IPMMA. 20,000 pharma trade professional/ decision makers and 250 industry majors will exhibit their technologies/ services. Visitors' profile include biotechnology specialists, plant management, CEOs, engineers, technocrats and scientists, policy makers, diplomats and foreign commercial corp, compliance, process engineering, corporate management, procurement department, custom manufacturing/ marketing

services, purchase officers, equipment suppliers and distributors, quality assurance/ quality control, maintenance engineering, R&D professionals, manufacturing/ production engineering, regulatory officers, operations management, validation, packaging engineering, vendor development, pharmacists.

Contact details Indian Pharma Machinery Manufacturers’ Association (IPMMA) 52, 1st floor, Suyog Industrial EstateLBS Marg, Vikhroli (West) Mumbai - 400 083 Tel: +91 22 6561 9272/ 2578 6007/ 2685 5108

EXPRESS PHARMA

21

October 16-31, 2014

cover )

22 EXPRESS PHARMA October 16-31, 2014

(

THE MAIN FOCUS

PACKAGING SPECIAL

(

To subscribe: bpd.subscription@expressindia.com

EXPRESS PHARMA

23

October 16-31, 2014

cover ) (L-R): Jasjit Singh, Ajit Singh and Karan Singh

T

he history of Indian pharma packaging machinery sector would be incomplete without mentioning Ajit Singh, Chairman of ACG Worldwide. His contribution to the industry has been immense as he has brought in a revolution in the attitude of Indian pharma machinery manufacturers — from 'can we?' to 'we can'.

Singh's success is a tale of struggle, efforts, persistence, confidence and dedication etc. Honesty and integrity have been his constant companions in this decades long journey.

A born fighter From setting up a small unit in the jungles of Kandivli, to establishing world-class plants in India and globally, Singh has come a long way.

Recollecting about his first unit and the challenges he faced in operating it, Singh narrates, “In the distant outreach of Greater Mumbai we had jungles and marshland around us. No city car could reach upto the factory. We went by horse and carriage for the last kilometre.” It is often found that there are picturesque scenarios waiting at the end of difficult terrains. It was true in Singh's case as well. From humble beginnings, Singh has become a name to be reckoned within the pharma packaging industry globally, today.

Like any new start-up, finding and retaining good managers was another problem for Singh, as also acquiring new technology. However, every obstacle was converted into an opportunity by him.

He informs, “We created managers by training and enthusing our workmen and supervi-

24 EXPRESS PHARMA October 16-31, 2014

Many honours and recognitions that have remained elusive to its domestic counterparts, came ACG's way, thanks to Singh's visionary leadership. The contribution of his brother Jasjit Singh, Managing Director of the company, also proved instrumental in the company's overall growth sors. The technology we had to develop by ourselves. Our growth perhaps took longer than it would have if we had gone public in the early years.

But the only time we were desperately short of cash was when we were putting up our new plant at Dahanu, now Asia’s largest capsule plant.”

He adds, “The erstwhile BCCI Bank was the only one that came to our rescue. I learnt some valuable marketing lessons from them. Overcoming problems in real life teaches you more than the best business school. We are glad we did not go public. We have retained enormous flexibility, and we can react to change with speed. We have now reached a size and growth that we don’t need to raise money by diluting our stock. Unlike many of our

global competitors, neither our plants nor people are for sale or purchase.”

Global recognitions Singh's considerable domain knowledge and expertise in pharma packaging helped him to raise his company to greater heights. His efforts received recognition from the industry and the governments in India and Croatia, where ACG has a plant.

“The Croatian Government, in public forums and TV, has twice described ACG as the ideal investor whom they welcome. In the last four years, two successive Presidents of Croatia have visited our plant at Ludbreg. They appreciated our efforts and contribution to Croatia in creating employment, innovation, technology creation and mak-

ing it the third largest supplier of capsules in Europe through export of 95 per cent of our production,” informs Singh.

He adds, “Our company has also been nominated to represent Croatia for a top European Business Award. In Brazil, we have been recognised by the Association of Pharma Manufacturers as the best supplier of pharma equipment and consumables.”

Why only ACG? Many honours and recognitions that have remained elusive to its domestic counterparts, came ACG's way, thanks to Singh's visionary leadership. The contribution of his brother Jasjit Singh, Managing Director of the company, also proved instrumental in the

company's overall growth.

“It was not easy. And we were determined. We generally do not get into any product line which is simple to get into, which needs only investment. Our leadership is largely due to our advanced technology and quality. And due to the talent and dedication of our people led by our Managing Director, Jasjit Singh. He is a brilliant engineer, and very modest. He’s also a great manager and much liked. His son and my nephew Karan, who’s increasingly taking over, displays strong, positive aspects of both of us,” informs Singh.

According to Singh, his company's achievements are a result of vision, patience, ambition, global networking, worldwide distribution and international advisors. Singh is optimistic about the growth of the industry as well. He says, “I’m sure other Indian manufacturers will also make their mark globally. They need to think long term and fortunately for them technology and manufacturing is now becoming a commodity. Acquiring proficiency here is not the great effort it was for us.

Though achieving consistent quality is.”

50 decades.... and going strong Singh is a walking encyclopedia on the pharma packaging industry. Many other big names in the industry have grown up in their respective domains by taking a leaf out of Singh's book of experience.

Who knows better about the ingredients of success than Singh himself?

“To remain for decades as a market leader and still keep going strong needs certain

(

THE MAIN FOCUS

NOTJUSTAN ENTREPRENEUR

attributes, a certain mindset, and some luck. As known, nine out of 10 start up businesses close down. Even the life span of a large, apparently strong company seldom equals that of its key personnel. The first attribute is a passion for the product and business – the more you focus on and understand your product and processes, the greater the passion becomes. Particularly, if you develop expertise and develop a size that makes your company and yourself respected worldwide in your field,” says Singh.

He adds, “Another requirement is to look after your people. Only if you nurture them and help them to grow will they have the motivation and commitment to look after your customers. And satisfied customers are a key reason for continued existence and survival of a business. To succeed, one needs to envision the future and plan for it.

Even better, to try and create it, or at least plan for it. Particularly important is planning for continuity and succession of key personnel. This is a delicate matter. My brother, Jasjit and I have worked out our own succession plan. Along with our very competent global head of HR Sunil Jha, we are now working on succession plans for other key positions. It is a difficult job, but, if not done it creates even more difficulty.”

It is the characteristic of a leader and a leading company to continuously reinvent the organisation and its products.

'Be Close to Your Customer' – is a constantly heard management jargon. According to Singh, it has a deeper meaning than giving great service, new varieties of product and

Stjepan Mesic, (then the President of Croatia) during his visit to ACG Lukaps in 2009. Also seen in the picture is Devendra Aajgaonkar

S

ingh’s business acumen is well known, however, he is also a philanthropist. One day he saw Devendra Aajgaonkar (now his personal assistant), working at the Fellowship for Physically Handicapped (FPH). Impressed by potential within this short man, he offered Devendra an opportunity to work with him. Since mideighties, Devendra has been a close confidant of Singh.“He made my life.

Because of him people treat me with respect, which otherwise I would not have got that easily,” says an emotional Devendra.

According to Devendra, Singh doesn’t like anybody calling him ‘Chotu’. His boss would

listening to customers. As an example, ACG group is involved in training over 2,000 professionals from the global pharma industry every year through seminars and in-house training. Singh asserts, “You need to be regarded as a source of knowledge and guidance, and be recognised not only as a supplier but also as a friend and colleague.”

Singh was lucky in a way that he had a completely trusted and competent partner.

In his case, it is his brother and life partner, Jasjit. Singh describes, “We work as a seamless unit, bringing our differing strengths to the business.

Some time back we were joined by my nephew Karan. He is a fast learner and combines the strengths of us both. In the last

To subscribe: bpd.subscription@expressindia.com

argue,‘Devendra is such a nice name, why should he be called Chotu?’ Devendra has visited countries like Germany and Croatia with Singh. He informs,“Singh would never hide his opinions about anything. He himself is a good human being and he likes to be among people with good moral values.”

Today the entire Indian pharma industry associates Devendra with ACG Worldwide and he gives all the credit to Singh for the same. Devendra has spent close to three decades at ACG and wants to continue his association with the company, and more importantly, with his boss, Singh.

ACG is a dream that Singh has lived day and night for several decades. He is as passionate about the company as he used to be 50 years back

few years we have also learnt, with great benefit, the importance of bringing in great team members often with competence greater than our own.”

Future expectations ACG is a dream that Singh has lived day and night for several decades. He is as passionate about the company as he used to be 50 years back.

Over the years, the company has achieved many milestones under his leadership and Singh wants his company to grow with the same spirit and enthusiasm.

He wants his company to be a world leader in each of its main products apart from being one of the best companies to work in, globally. Being a caring person by nature,

Singh wants to continue to make products for the pharma industry that improves health and well being, reduce pain and suffering and continue to get the blessings of people from around the world billions of times a year.

Singh feels that a vital ingredient for continued success is to be very conscious of your inadequacies and missed opportunities. And learn from them. “Though we may become a world leader in sales of product lines we need to learn how to think and, more importantly, act like a world leader.

But we are getting there,” says a humble Singh.

Conclusion Associating Singh only to his company would be an injustice to his hard work in the last many decades. Today, he represents not just ACG Worldwide but the entire Indian pharma packaging machinery sector in the global market.

Singh has achieved a lot today but like a true entrepreneur he always believes in taking a step further. Instead of predicting the future he wants to create the future and this thinking makes him stand apart from his colleagues in the industry.

American philosopher, Andrew Bernstein's words, “The hero is the man who lets no obstacle prevent him from pursuing the values he has chosen,” describes Singh to a 'T'.

The Indian pharma machinery manufacturing industry has matured a lot over the last few years. Its overseas counterparts are looking at it as a serious competition. To keep this competitive edge alive, the role of a visionary like Singh would prove crucial. sachin.jagdale@expressindia.com

EXPRESS PHARMA

25

October 16-31, 2014

MANAGEMENT

26 EXPRESS PHARMA October 16-31, 2014

To subscribe: bpd.subscription@expressindia.com

EXPRESS PHARMA

27

October 16-31, 2014

MANAGEMENT

R

ecently the Government of India has identified 25 key sectors in which India has the potential of becoming a world leader and the pharmaceutical sector is one of them. And, with an aim to turn the country into a global manufacturing hub, to ensure that India is not treated as a ‘Market’, and to retain homegrown talent, on September 25, 2014, Prime Minister (PM) Narendra Modi (Just before his first visit to US after becoming the prime minister of India) launched the ‘Make In India’ campaign.

Responding to the ‘Make In India’ campaign, Kiran Mazumdar-Shaw, Chairman and Managing Director, Biocon comments, “Make In India campaign reflects PM Modi’s

commitment to make India the preferred global destination for manufacturing. His assurance towards ‘Ease of Business’ and ‘Speed of Business’ through simplified rules and self regulation, is likely to win investor confidence and usher in a new wave of investments in the country.”

Dr Rajaram Samant, Chief Executive Officer and Chief Mentor, Akumentis Healthcare says, “This is a great initiative by our PM to give push to Indian manufacturing sector. In fact, the pharma manufacturing sector is making news globally. India is likely to emerge as third biggest market globally in terms of volumes after the US and China.

A word of caution ‘We need to commit to global quality standards’ to turn this vision in to

reality and make India shine.”

Thus it seems that the ‘Make in India’ campaign has been received well within the country, however, the global scenario doesn’t seem very conducive for its success at this point of time.

Stiff competition China, one of our strongest competitors has also launched a similar, ‘Made in China’ campaign with a host of tax concessions to boost its manufacturing prowess. India imports nearly 60 -70 per cent of its required active pharmaceutical ingredients (APIs) from China and is still largely dependent on the Chinese APIs manufacturers.

Reputation at stake Right before the Indian PM’s

visit to US, Washington-based American Enterprise Institute (AEI) published the findings of a ‘study’ as a working paper in the National Bureau of Economic Research (NBER) series. The study claims to assess “the quality of 1470 antibiotic and tuberculosis drug samples that claim to be made in India and were sold in Africa, India, and five mid-income non-African countries” based on samples “from pharmacies in 22 cities of 18 low- to mid-income countries between 2009 and 2012.”

The India Brand Equity Foundation (IBEF), on behalf of the Government of India (GoI), has taken a strong objection to the study and called it “a smear campaign being orchestrated by the AEI against the whole Indian

n October 2013,the US FDA had inspected Amanta Healthcare’s (formerly known as Marck Biosciences),manufacturing facilities located in Kheda,Gujarat.The company is a specialist in manufacturing and marketing of sterile dosages and blow-fill-seal (BFS).The US FDA regulators made several observations, including on various aspects of documentation and maintenance of records as well as issues outside the facility.The company claims that it has submitted all required documents to the authority within one months time and gets the warning letter from the US FDA on 8 July,2014.It is important to note that the facility has been certified by MCC South Africa,TGAAustralia,MCAZZimbabwe,UK MHRA,SGS (Malaysia) and SGS India.

One of the interesting aspect in this case is that the company has no exports to the US market as of now nor it has any immediate plans.However,it intends to take all the US FDA’s observations extremely seriously and reapply for certification within the next 12 months.Bhavesh Patel,Managing Director, Amanta Healthcare shares,“At the time of inspection,we didn’t have any business in the US markets.However,we are working on the product pipeline and we intend to achieve full compliance meeting US FDAwithin 12 months.”

28 EXPRESS PHARMA October 16-31, 2014

US FDA had inspected the company’s Kheda facility in October 2013 and 18 observations were made.Patel shares the key finding of the US FDA inspection,“In some cases,the US FDA report have been ambiguous and left to imagination.The dead frogs were found outside the exit door,closer to our construction site.It was not and cannot be inside the manufacturing block.

Subsequent inspections have taken the cognition of this fact.Subsequent to those observations,we submitted corrective action plan and compliance within the stipulated 21 working days i.e.by the end of November 2013.

We also had attached relevant photos of corrective action taken wherever required and possible in our compliance report.”

According to the company sources,US FDA, as a matter of practice,had shared this report with UK MHRA.And few weeks later,UK MHRA team consisting of two members spent five days at the company’s site and were satisfied with the company’s compliances procedures.The UK MHRA team had also met the commissioner of Gujarat FDA before and after inspection and expressed their satisfaction.

For renewal of CE certification,UK MHRA had directed SGS Malaysia to inspect the plant and cleared the facility.UK MHRA and SGS

Kiran MazumdarShaw, CMD, Biocon

A CASE STUDY OFAMANTA HEALTHCARE

I

PM Modi's assurance towards ‘Ease of Business’ and ‘Speed of Business’ through simplified rules and self regulation, is likely to win investor confidence and usher in a new wave of investments in the country

inspection were specifically focussed on observation made by US FDA.Patel informs, “All these inspections subsequent to the FDA survey have found that Amanta had satisfactorily met the requirements and no adverse observation or comments or advisory was issued.After US FDA inspection,the company responded with thorough compliance and in subsequent inspection by UK MHRA and SGS Malaysia.We could show them the same compliance.They had an opportunity to see ground reality which probably resulted in both compliances.”

Mistake known to be a best teacher which teaches from its last mistake.And a smart person always learns a lesson from its last mistakes and never repeats it in future.Patel shares learnings from the US FDAwarning letter and comments,“We face more than 100 inspections a year from various regulatory authorities and customers.Every inspection had potentially a learning value.No organisation can be build based on one or two experiences.It’s a process by itself.”

He continues,“We are having manufacturing partnership with some of reputed pharma companies.We are glad that we have met their expectations and with the same spirit we intend to meet US FDA’s expectations as well.”

It is incorrect to say that Indian companies are not following set standards and are incapable of delivering quality medicines to the world. If it was indeed so, the exports would not have grown year after year at 18 to 20 per cent per year and reached $13 billion DG Shah, Secretary General, Indian Pharmaceutical Alliance

MANAGEMENT

There seems to be a deliberate campaign to malign the Indian pharma industry Dr PV Appaji, Director General, Pharmexcil India

pharma industry. It seems that the effort is to tarnish the image of the Indian pharma industry which it has painstakingly developed over the years and is often recognised as ‘Pharmacy of the World’”. The conclusions of the study are disputed not only for methodology and ethics but also for the poor treatment of data sampling used.

Protesting against the study, Dr PV Appaji, Director General, Pharmexcil India highlights the lack of ethics in the study and says, “There seems to be a deliberate campaign to malign the Indian pharma industry. The minimum requirement would be to give an opportunity to the labelled manufacturers to give their comments against their test observations.”

DG Shah, Secretary General, Indian Pharmaceutical Alliance (IPA) takes up a strong stand and says, “The study recognises that products with “Made in India” label may not be actually made in India. The study also recognises that transportation and storage conditions could have impacted the quality of products. But ignoring these realities, it still attributes poor quality (of drugs at the consumer end) to manufacturers and the Indian pharma regulator.” This is not only strange but reflects of a smear campaign with an ulterior motive rather than actually being concerned about quality issues.”

RS

Ready-to-Sterilize Components

Ready-to-Sterilize Packaging and Syringe Components

Low in bioburden and particulate

Pharmaceutical manufacturers around the world choose Westar ready-to-sterilize components for packaging their injectable drugs. Westar components can help streamline your filling and packaging operation and may help reduce your documentation requirements for regulatory filings. With West, you have a partner by your side from discovery to the patient.

Can be introduced directly into a steam autoclave Help streamline manufacturing processes

To subscribe: bpd.subscription@expressindia.com

Contact West today. +91 40 4940 1111 Literature.AsiaPacific@westpharma.com www.westpharma.com West and the diamond logo, Westar® and By your side for a healthier world™ are trademarks or registered trademarks of West Pharmaceutical Services, Inc., in the United States and other jurisdictions.

Copyright ©2013 West Pharmaceutical Services, Inc. #7598

EXPRESS PHARMA

29

October 16-31, 2014

MANAGEMENT Appaji points out at least eight technical issues with the sampling and data techniques, “Samples were not authenticated either from the source or from the regulators of the local country; samples were not referred to manufacturers to ascertain their genuineness. Authors have not ascertained the source of supply of the drug and not indicated in the report. They directly pointed out that they are from India; the names of the manufacturing firms were not disclosed; the study fails to indicate the reference standards used. Based on the above observations, the report has no value on the face but they have published this report to damage the image of India in the international market.”

Sudhanshu Pandey, Joint Secretary, Department of Commerce, Government of India comments, “Quality is one of the major focus for pharma exports from India.

Indian companies meet the quality requirements of all our importing countries. India looks at healthcare as a holistic issue rather than just commercial business.”

US FDA alerts In the last one and half years’, India’s reputation as ‘Pharmacy of the World’ has been

somewhat tarnished in the global pharma space. Pharma exports from India to the US have been in the news, but for the wrong reasons as there have been constant regulatory alerts from the US FDA authority.

India has the maximum number of US FDA approved facilities outside the US, but in the last one and half years many Indian pharma firms have received warning letters, 483s or import alerts due to data reliability/integrity issues. Ranbaxy, Wockhardt, Sun Pharma are the most affected Indian pharma firms and there are many more midsized pharma companies who have come under the US FDA scanner in the recent past. India is not the only country who has been receiving the US FDA warning letters. Pharma firms from other countries including the US and Europe have also received warnings from the US regulatory authority, yet the slant put on the warning letters received to Indian firms have been completely different. As a result the brand reputation of the Indian pharma industry has been adversely impacted.

On a larger spectrum it shows that Indian pharma companies are not following set standards and are inca-

pable of delivering quality medicines to the world. It also questions the capability of the Indian regulatory mechanism as many of these manufacturing facilities (Under US FDA scanner) are approved by the Indian regulators. However, the Indian pharma industry believes that it is being victimised and the hype has hurt the image of Indian pharma industry.

Shah says, “It is incorrect to say that Indian companies are not following set standards and are incapable of delivering quality medicines to the world. If it was indeed so, the exports would not have grown year after year at 18 to 20 per cent per year and reached $13 billion.”

Commenting on the US FDA warning letters, Dr Ajit Dangi, President and Chief Executive Officer, Danssen Consulting says, “Statistically, incidence of the number of such US FDA warnings compared to the total number of US FDA approved manufacturing facilities and ANDA/DMF/ FTFs granted which are highest in the world outside US, appear to be hyped.”

He emphasises, “It is important to distinguish between GMP non-compliance and outright frauds. For in-

stance, the Ranbaxy matter came to light due to whistleblowing by its own scientist Dr Dinesh Thakur.” He also admits, “The primary responsibility for producing and marketing a safe and efficacious product is that of the manufacturers. This is why the quality assurance starts from the top management of the company. If the CEO of the company is not conscious about the quality standards the same cannot be imbibed in the junior level personnel.

Hence, the top management needs to be fully aware of implications and the risks involved in non conformance of quality.”

SV Veerramani, President, IDMA informs, “I think, the multiple warning letters are confined to a few companies and more so in the areas of documentation, rather than the quality of the finished products. The hype with respect to India is more to put down the image of the Indian pharma industry, which is providing pharma products to more than 200 countries.”

He further adds that Indian pharma companies has come a long way and today is considered as one strong force which can really take on the world market. He further recommends immaculate and

The basic weakness in Indian regulatory framework is that we lack a central regulatory authority that is similar to US FDA Dr Ajit Dangi, President and CEO, Danssen Consulting

The hype with respect to India is more to put down the image of the Indian pharma industry, which is providing pharma to more than 200 countries S V Veerramani, President, IDMA

KEY STEPS TO RE-BUILD THE INDUSTRY'S IMAGE IN THE GLOBAL PHARMAWORLD DR AJIT DANGI ◗ It is important to have a written down whistleblower policy where any employee of the company no matter how junior, should be able to get in touch with a board member and report any wrongdoings in the company. ◗ Companies need to conduct regular training programmes on ethics and good governance for the employees and keep them updated on new laws,regulatory changes which are taking place globally.

Training in behavioural modification to develop culture of Zero Tolerance to non conformance needs to be given periodically. ◗ While testing the finished product for quality is important, it cannot guarantee good quality consistently. The company

30 EXPRESS PHARMA October 16-31, 2014

needs to adopt Quality by Design (QbD) structure to assure good product quality consistently. The focus should be to build quality in to the product at every stage with thorough understanding of the product and processes through which it is developed and the knowledge of the risk involved in non conformance.

SV VEERAMANI ◗ Implement and build concept of UNLEARNING and RELEARNING into GMP systems of the company. Basics of building quality to the product from formulation development level till it is approved and passed for marketing by QA has to be taken with utmost seriousness including documentation process. Training programme for employees at all levels to be

implemented and monitored stringently to ensure every employee will RELEARN right things and right way. Annual employee evaluation to include additional criteria of measuring current knowledge levels on his area of expertise. This can be done in-house or outside expertise can be used. It is important for every company to make their employees understand their commitment to GLOBAL healthcare. It has to percolate TOP down and employee should be made aware that any wilful wrong doings (if proved) affecting image of the company and that of the country will not be taken lightly. ◗ Build up the image of Indian Pharmaceuticals through Media and Promotions. ◗ To make all the corrective actions as necessary and provide confidence to the buying countries including US.

We are working with industry stakeholders, including regulators, to ensure Indian pharma’s positioning as a responsible healthcare provider Aparna Dutt Sharma, CEO of India Brand Equity Foundation

MANAGEMENT legible documentation, proper following of laid down QMS and recording of data with scientific reasoning for further progress of the Indian pharma in the next couple of years at a fast pace.

However, the industry also accepts that there is an urgent need to rebuild the image of Indian pharma and bring back the trust that it has lost.

Image re-building Speaking on the measures being implemented to achieve this aim, Aparna Dutt Sharma, Chief Executive Officer, India Brand Equity Foundation (IBEF) comments, “India is known as the pharmacy to the world. The recent opening of markets like Argentina and the opportunities in Japan, indicate the position that Indian pharma occupies in the world. We are

working with industry stakeholders, including regulators, to ensure Indian pharma’s positioning as a responsible healthcare provider.”

Pointing out that regulators play an important role in buildingt the image of an industry in the global market, Dangi says, “The basic weakness in Indian regulatory framework is that we lack a Central Regulatory Authority that is similar to the US FDA. The Union Cabinet proposed and approved the formation of Central Drug Authority (CDA) way back in the year 2005, however, due to vested interests, the plan was put on a back burner. While India has Central Drugs Act, its implementation is carried out by states in varying forms. While some states like Maharashtra, Gujarat, Karnataka etc. have a reasonably good regulatory set

To subscribe: bpd.subscription@expressindia.com

India is likely to emerge as third biggest market globally in terms of volumes after the US and China. Word of caution ‘We need to commit to global quality standards’ to turn this vision in to reality and make India shine Dr Rajaram Samant, CEO and Chief Mentor, Akumentis Healthcare

up, some of the smaller states have a very weak set up to say the least. Unfortunately, drugs manufactured in such states can be marketed all over India.”

Thus while the country has some good examples of streamlines regulatory processes, there is a need to implement them across India backed by good governance. Veeramani opines, “Current crop of regulators, be it state or central, there is a good trend in their approach which can be seen during respective GMP audits. It would do good to many serious pharma players if the regulators can play the role of mentors than regulators. Indian regulators can also participate actively in the International Forums of Global Regulators.”

Dangi spells, “If this trend continues, not only it will tarnish the reputation of Indian

pharma industry globally but may impact ANDA/DMF / FTF approvals due to additional scrutiny resulting in more delays in drug approval process.”

He continues, “Now that the US FDA has a dedicated team for India, led by US FDA Country Director, India, Dr Altaf Lal, industry seniors should have a continuous dialogue with them to understand the US FDA requirements and to iron out any real or perceived differences to maintain our reputation of being a reliable source of quality medicines at affordable prices.”

Mazumdar sums up and says, “Modi’s commitment to FDI, ‘First Develop India’, resonates well with the industry.

India needs to align democracy, demographic dividend and demand to make India the global manufacturing hub. However, we need to benchmark some of

EXPRESS PHARMA

31

October 16-31, 2014

MANAGEMENT our policies related to manufacturing, labour laws, land acquisition, environment, health and safety, with some of the best countries in the world. We must address infrastructure challenges related to power and water, roads and railways on priority for ‘Make In India’ campaign to be really successful.”

The way forward Recognising the need for some constructive action to mitigate the challenges in Indian pharma and bring it back to its earlier glory, the Government of India and major pharma industry organisations namely

Company

Indian Pharmaceutical Alliance (IPA), Indian Drug Manufacturers’ Association (IDMA), Association of Biotechnology Led Enterprises (ABLE), Bulk Drug Manufacturers Association (BDMA), Pharmaceutical Export Promotion Council of India (Pharmexcil) and India Brand Equity Foundation (lBEF) have come together to form the 'India – Responsible Healthcare Trust' to power the Brand India Pharma campaign, which was launched under the aegis of the Department of Commerce at CPhI Japan in March 2012.

Plant

Responsible Healthcare Trust represents the commitment to both drive and safeguard the interests of the industry

Nature of voliations

A one-of-its-kind public-private partnership, the formation of the Trust represents the commitment to both drive and safeguard the interests of the Indian pharma industry. The Trust chaired by the Commerce Secretary comprises key stakeholders from above mentioned associations. It aims to combine both financial and non-financial resources towards a common agenda, create better awareness and develop an informed perspective about ‘Brand India Pharma’ in both the domestic and global markets. This spreads a strong message to the world community.

On an inaugural launch of the entity, Rajeev Kher, Commerce Secretary, Government of India. highlights, “The India – Responsible Healthcare Trust will spearhead the Brand India Pharma initiative through the second phase. The industrygovernment partnership is an important milestone in the campaign. ” Hopefully, the government's new initiatives and industry associations' efforts will help the industry to overcome all the challenges and pave the path for further progress. u.sharma@expressindia.com

Status

Date of import alert

Latest warning letter date

2014 Sun Pharmaceuticals

Karkhadi , Gujarat

Violations of (cGMP) regulations for formulations & API's

Import Alert

13-Mar-2014

7-May-2014

Apotex Pharmachem India

Bommasandra, Banglore

Violations of (cGMP) regulations for API's

Import Alert

1-Apr-2014

16-Jun-2014

Apotex Research Private Limited

Bommasandra, Banglore

Violations of (cGMP) regulations for formulations

Import Alert

22-Sep-2014

USV

Govandi , Mumbai

Violations of (cGMP) regulations for formulations

6-Feb-2014

Marck Biosciences

Kheda , Gujarat

Violations of (cGMP) regulations for formulations

8-Jul-2014

Smruthi Organics

Solapur, Maharastra

Violations of (cGMP) regulations for API's

6-Mar-2014

Canton Laboratories

Vadodara, Gujarat

Violations of (cGMP) regulations for API's

27-Feb-2014

2013 Agila Specialties

Bommasandra, Banglore

Violations of (CGMP) regulations for formulations

9-Sep-2013

Posh Chemicals

Jeedimetla, Hyderabad

Violations of (cGMP) regulations for API's

2-Aug-2013

Wockhardt

Chikalthana, Maharastra

Violations of (cGMP) regulations for finished pharmaceuticals

Import Alert

26-Nov-2013

25-Nov-2013

Wockhardt

Waluj, Maharastra

Violations of (cGMP) regulations for finished pharmaceuticals

Import Alert

22-May-2013

18-Jul-2013

Aarti Drug

Tarapur , Maharastra

Violations of (cGMP) regulations for finished pharmaceuticals

RPG Life Sciences

Ankleshwar & Thane-Belapur , Maharastra

Violations of (cGMP) regulations for finished pharmaceuticals

Hospira

Irungattukottai,Tamil Nadu

Violations of (cGMP) regulations for finished pharmaceuticals

Ranbaxy Laboratories

Mohali, Punjab

Violations of (cGMP) regulations for finished pharmaceuticals

Import Alert

13-Sep-2013

Micro Labs

Banglore and Goa

Violations of (cGMP) regulations for finished pharmaceuticals

Import Alert

21-Aug-2013 and 9-19-2014

Wintac

Nelamangala, Karnataka

Violations of (cGMP) regulations for finished pharmaceuticals

30-Jul-2013 Import Alert

11-Jun-2013 and 10-Jun2013

28-May-2013 28-May-2013

2012

(Sources: Angel Broking )

32 EXPRESS PHARMA October 16-31, 2014

23-Feb-2012

MANAGEMENT I N T E R V I E W

‘IRHT would focus on Africa, Japan and Latin America as potential markets of the future’ India Brand Equity Foundation has been at the forefront of positioning Brand India Pharma and has taken up the mantle to further enhance India’s value proposition at international forums such as CPhI. Aparna Dutt Sharma, Chief Executive Officer, India Brand Equity Foundation (IBEF) reveals more in a candid interview with Shalini Gupta

Tell us something about the inception of “Brand India Pharma” and the journey so far.

In 2014, the Brand India Pharma campaign is in its second phase. It was formalised and initiated painstakingly over an year-long period and was launched in 2012 at CPhI Japan. We picked up a market like Japan, known to follow some very strict policy standards, because we wanted to project and highlight the fact that India stands up to its value proposition adhering to the highest quality standards. When we began the campaign, at the core we had positioned the tagline- “Pharmacy of the world” which projects India's role as a generics producer being among the big league when it comes to generic formulation exporters in volume terms. India also has been ranked high when it comes to providing medicines and formulations to NGOs as per WHO requirements. We wanted the world to understand that India represents credible, affordable and sustainable solutions in healthcare. It was extremely well received within the country.

Moving forward, we realised that it was time that we used the CPhI platform, which is perhaps the biggest pharmaceutical exhibition in the world to leverage this

We wanted the world to understand that India represents credible, affordable and sustainable solutions in healthcare EXPRESS PHARMA

33

October 16-31, 2014

MANAGEMENT

opportunity to relay the message that India would like to communicate to the world at large. While larger companies make their presence felt by virtue of the scale and size that they represent, companies that come under Pharmexcil are SMEs which don't enjoy the same recognition as their bigger peers despite the fact that they have achievements to their credit. We felt that this messaging was getting lost and so IBEF made sure to position Brand India Pharma strongly by moving from corner positions to the high table by negotiating for a central position at the India pavillion. It was the first time that we were recognised as a value partner. We engaged thoroughly with editors from pharma trade journals across the world and organised interactions with representatives from Pharmexcil, senior officials from Department of Commerce which created a better understanding of the Indian Pharma industry. With more than 2000 stands at the fair, IBEF, got a recognition when we did not undertake a PR exercise. At Frankfurt, it went one step further, as global media editors requested us for interactions with senior officials to try and understand the change which has transpired within the Indian industry, as to how are they tackling quality issues, what are the mechanisms they have put in place etc. In short, we made our voice heard.

IBEF must be representing other sectors as well when it comes to Brand India. How is pharma as a sector different in terms of branding? The campaign began in 2012, why did we start branding pharma so late?

We are engaged in sectoral campaigns for tea, coffee, spice and the engineering sector .

Every sector has its own distinct characteristics. Brand recognition for India as a country has been in the IT sector since 2000. The thinking in the Department of

34 EXPRESS PHARMA October 16-31, 2014

Brand India Pharma campaign brings an opportunity to respond in a timely manner and present a perspective so that both the perspectives are presented to the world before an opinion is formed. IBEF is essentially looking at developing a forum wherein stakeholders start recognising the challenges and the necessity to respond to them with immediacy Commerce has been that apart from IT, which has done well, sectors such as pharma have credentials and achievement to their credit which need to be communicated to the world.

The campaign didn't start late, but private companies have been positioning themselves with the campaign concretely directed at helping the SME sector specifically to ensure that they are able to position themselves with strength. The idea has been that with India playing such an important role in the generics field and providing credible, affordable and sustainable solutions to the world, this distinct value proposition needs to be heard.

This is what motivated the Department of Commerce and especially the Commerce Secretary to get the campaign together and say that, if IT was the solution for competitive edge and pricing, pharmaceuticals bring in an competitive edge with volumes, quality and more importantly a global solution for the world, not only for comparable economies but also for developed economies. Export figures elucidate this better with India's pharma industry accounting for 1.4 per cent of the global pie by value and 10 per cent by volume.

We account for the fourth largest in market share in Asia Pacific with a CAGR of 21 per cent over the last few years. Hence, there was a strong case to take, consolidate these facts and communicate this to the world.

We have been a generics capital but the future belongs to biosimilars and other riskier territories which present the next big opportunity with a lot of companies venturing into these areas. On that front, how are you positioning Brand Pharma?

When we started, at the core we had positioned India as the pharmacy of the world with the generic aspect. In stage two the positioning has been further amplified. The tagline now talks about India as a responsible health provider. It is extremely important for the world to understand that there is an emphasis on credible and quality solutions that India stands for. We are reemphasising this point.

Recently, we also formed the special purpose vehicle (SPV), which is the India Responsible Healthcare Trust (IRHT), the first PPP in the pharma sector. It is a unique initiative between the government and apex industry associations with the Commerce Secretary as its Chairman and important players such as IPA, IDMA, ABLE, IBEF etc. who discuss and debate important issues impacting the industry. It is a core group which is represented by its Director General or Secretary General.

The idea is to build and synergise trends on both sides and leverage it towards a common agenda which can then be internalised by these associations and then carried forward.

What are the goals and objectives that IRHT has set up for itself?

Our trust deed has been outlined and shall be formalised soon. Definitely there is agreement across the table on two points-better communication and creating an improvement in understanding and awareness levels of the Indian pharma industry along with a commitment by both sides to drive and safeguard the interests of the industry.

Those are the twin objectives at the core of the trust. One is looking at the trust to take the initiative to the next level. This is a milestone achievement for us given the fact that when we started we were undertaking this project under the aegis of the Department of Commerce and Pharmexcil and industry started noticing the strategic branding that we started doing at CPhI and they started approaching and applauded IBEF for its efforts. They understood that the government was making serious efforts and that is the value proposition they wanted to combine their energies with.

The last one year has been challenging for the industry with its image dented with US FDA alerts, substandard drugs as well as regulatory hurdles etc. Your comments.

We live in a changing context. Part of the initiative is understanding the value proposition that Indian Pharma represents. Most of the times we have found that these articles coming into the

press have been unilateral with singular reporting. We haven't been responding to these in a timely manner.

Brand India Pharma campaign brings an opportunity to respond in a timely manner and present a perspective so that both the perspectives are presented to the world before an opinion is formed. We create a communication channel to understand real issues and respond to them accordingly. If countries and companies have a PR positioning, it is high time for us to be responding.

Leveraging similar mechanisms to position our perspective. Especially when you come across pressure groups, it is open to logic, to say that we are welcome to debate. IBEF is essentially looking at developing a forum wherein stakeholders start recognising the challenges and the necessity to respond to them with immediacy.

What are tangible goals that IBEF has set for itself?

Today, we are working with different export promotion councils. Branding in any form as an communication exercise should create better understanding and awareness of the sector, what it represents, and create a more welcoming environment for our industry in different markets. A lot of markets thrive in perception, which lags reality. It is important for us to fill in that gap and engage with possible stakeholders in potential markets to make them understand the sectors value proposition and if they find value in the sector and taking it forward. We would continue to focus on existing markets such as the US and the UK. IRHT would focus on markets including Africa, Japan (in the medium term) and Latin America as potential markets of the future. We have zeroed upon these on the existing performance of the companies in these markets and their potential. shalini.g@expressindia.com

RESEARCH CLINICAL UPDATE

Novartis’Gilenya reduces brain shrinkage matters for people with MS Patients who had the highest rates of brain shrinkage at two years had a higher risk of disability progression at four years NOVARTIS' NEW data reinforces the clinical importance of measuring brain shrinkage (brain volume loss) in multiple sclerosis (MS). An association between the rate of brain shrinkage and increased risk of long-term disability progression was confirmed in patients with MS[1]. In pooled data from the phase III Freedoms core and extension studies, patients were categorised into four groups (quartiles) based on the mean change in brain volume from the start of the study to year-two. The analysis showed that 24.2 per cent of patients who had the highest rate of brain shrinkage at two years had confirmed six-month disability progression at four years, compared to 15.4 per cent of patients with the lowest rate of brain shrinkage (p=0.018)[1].

A separate analysis from the longterm follow-up extension study Longterms, showed that the rate of brain shrinkage in patients treated with Gilenya (fingolimod) remained similar throughout the six-year period, between 0.33 per cent and 0.46 per cent [2]. This was broadly in the range you would expect to see in people without MS, while the typical rate of brain shrinkage experienced by patients with MS is approximately 0.5 per cent to 1.35 per cent per year[3],[4],[5],[6].

"Novartis is committed to generating data that advances science and clinical practice to improve the outcomes of patients. These new findings strengthen the link between brain shrinkage and long-term disability progression, supporting the significance of brain shrinkage for people

with MS," said Vasant Narasimhan, Global Head of Development at Novartis Pharmaceuticals. "The new data showing sustained low rates of brain shrinkage in Gilenya-treated patients with MS are reassuring because of the chronic debilitating nature of the disease."

The rate of brain shrinkage for people with MS is around three to five times faster than people without the disease[3],[4],[5],[6], and what is lost cannot be recovered. Brain shrinkage can start early[7],[8],[9],[10], often goes unnoticed and is associated with a loss of physical and cognitive (i.e. memory) function for patients with MS[11].

Analyses of the pooled data from the phase III Freedoms core and extension studies showed that irrespective of treatment received brain shrinkage was associated with future long-term disability progression[2].

EXPRESS PHARMA

35

October 16-31, 2014

RESEARCH References [1] Jeffrey D et al. Brain volume change by quartile and disability progression in multiple sclerosis: a 4-year analysis of the phase 3 FREEDOMS trial and its extension. Abstract presented at: 2014 Joint ACTRIMSECTRIMS Meeting; September 10-13, 2014; Boston, Massachusetts. Abstract 36. Free communication FC2.3.

[2] Radue E.W. et al. Sustained low rate of brain volume loss under long-term fingolimod treat-

ment in relapsing multiple sclerosis: Results from the LONGTERMS study. Abstract presented at: 2014 Joint ACTRIMS-ECTRIMS Meeting; September 10-13, 2014; Boston, Massachusetts. Abstract 1346.

Poster 439.

[3] De Stefano N et al. Proportion of patients with BVL comparable to healthy adults in fingolimod phase 3 MS studies.

Abstract presented at: 66th AAN Annual Meeting; April 26 - May 3, 2014; Philadelphia,

Pennsylvania. Oral session S13:006.

[4] Barkhof F et al. Imaging outcomes for neuroprotection and repair in multiple sclerosis trials.

Nat Rev Neurol. 2009;5(5):256266.

[5] Bermel RA & Bakshi R. The measurement and clinical relevance of brain atrophy in multiple sclerosis. Lancet Neurol.

2006;5(2):158-170.

[6] Hedman AM et al. Human Brain Changes Across the Life Span: a review of 56 longitudi-

nal magnetic resonance imaging studies. Human Brain Mapping 2012; 33: 1987-220 [7] Di Stefano N et al. Clinical Relevance of Brain Volume Measures in Multiple Sclerosis. CNS Drugs 2014; published online January 22, 2014.

[8] PĂŠrez-Miralles F et al. Clinical impact of early brain atrophy in clinically isolated syndromes.

Mult Scler. Published online: May 7, 2013.

[9] Filippi M et al. Evidence for widespread axonal damage at

Schizophrenia has group of eight genetically distinct disorders That makes it almost impossible for people with those genetic variations to avoid the condition. In all, the researchers identified 42 clusters of genetic variations that dramatically increased the risk of schizophrenia.

Dragan Svrakic, a co-investigator and a professor of psychiatry at Washington University, said when the research team organised the genetic variations and the patients' symptoms into groups they could see that particular clusters of DNA variations acted together to cause specific types of symptoms.

Researchers then divided patients according to the type and severity of their symptoms, such as different types of hallucinations or delusions, and other symptoms, such as lack of initiative, problems organising thoughts or a lack of connection between emotions and thoughts. The results indicated that those symptom profiles describe eight qualitatively distinct disorders based on underlying genetic conditions.

THE US Food and Drug Administration has designated Israel’s BrainStorm Cell Therapeutics adult stem cell treatment as a 'fasttrack' product for the treatment of amyotrophic lateral sclerosis (ALS).

BrainStorm's treatment, called NurOwn, is being studied in a midstage clinical trial in patients with ALS, also known as Lou Gehrig's Disease.

The FDA's fast track programme is designed to speed up access to drugs intended to treat serious conditions and which have the potential to address unmet medical needs.

"The receipt of fast-track designation from the FDA is an acknowledgement of the unmet medical need in ALS," Tony Fiorino, Chief Executive Officer, BrainStorm.

"What is so valuable about fast track designation to a small company like BrainStorm is the opportunity to have increased meetings with and more frequent written communication from the FDA," he said, adding that only a small number of cellular therapies have received FDA approval.

BrainStorm said the last patient has completed the last visit in its phase 2a clinical trial in ALS at Hadassah Medical Center in Jerusalem. The company expects to release final results of the study in the fourth quarter of 2014.

PTI

Reuters

Study could be a first step towards improved diagnosis and treatment for the debilitating psychiatric illness

36 EXPRESS PHARMA October 16-31, 2014

ten referred to as a single nucleotide polymorphism (SNP).

They looked at SNPs in 4,200 people with schizophrenia and 3,800 healthy controls, learning how individual genetic variations interacted with each other to produce the illness.

In some patients with hallucinations or delusions, for example, the researchers matched distinct genetic features to patients' symptoms, demonstrating that specific genetic variations interacted to

create a 95 per cent certainty of schizophrenia.

In another group, they found that disorganised speech and behaviour were specifically associated with a set of DNA variations that carried a 100 per cent risk of schizophrenia.

Although individual genes have only weak and inconsistent associations with schizophrenia, groups of interacting gene clusters create an extremely high and consistent risk of illness, on the order of 70 to 100 per cent.

EP News Bureau-Mumbai

BrainStorm gets US FDAnod

RESEARCH UPDATES

SCHIZOPHRENIA IS not a single disease but a group of eight genetically distinct disorders, each with its own set of symptoms, scientists have found. The finding could be a first step toward improved diagnosis and treatment for the debilitating psychiatric illness, said researchers at Washington University School of Medicine in St Louis.

About 80 per cent of the risk for schizophrenia is known to be inherited, but scientists have struggled to identify specific genes for the condition.

Researchers in the new study analysed genetic influences on more than 4,000 people with schizophrenia and identified distinct gene clusters that contribute to eight different classes of schizophrenia.

C Robert Cloninger, one of the study's senior investigators, and his colleagues matched precise DNA variations in people with and without schizophrenia to symptoms in individual patients.

In all, the researchers analysed nearly 700,000 sites within the genome where a single unit of DNA is changed, of-

the earliest clinical stage of multiple sclerosis.

Brain.

2003;126(Pt 2):433-437.

[10] Filippi M et al. The contribution of MRI in assessing cognitive impairment in multiple sclerosis.

Neurology 2010; 75: 2121-28.

[11] Popescu V. et al; on behalf of the MAGNIMS Study Group.

Brain atrophy and lesion load predict long term disability in multiple sclerosis. J Neurol Neurosurg Psychiatry. Mar 23, 2013.

RESEARCH

Nobel discovery opens window onto Alzheimer’s disease Global cases of dementia are expected to treble by 2050 THE DISCOVERY of cells in the brain that act as the body's internal global positioning system, which won three scientists the Nobel Prize for medicine, opens an intriguing new window onto dementia.

Since these spatial cells are among the first to be hit in Alzheimer's and other forms of dementia, explaining why sufferers often lose their way, understanding how they are degraded should shed important light on the disease process.

That is the belief of British-American researcher John O'Keefe, winner of the 2014 prize alongside Norwegians May-Britt and Edvard Moser, who plans to take his research to the next level as director of a new brain institute in London.

"We're now setting up to do much more high-tech studies where we hope to follow the progression of disease over time," he said after hearing he would share the 8 million Swedish crowns ($1.1 million) prize.

The battle against Alzheimer's has been long and frustrating. Global cases of dementia are expected to treble by 2050, yet scientists are still struggling to understand its basic biology and drug development is littered with failures.

The work by O'Keefe and the Mosers will not lead to immediate breakthroughs but by explaining how cells function, and then fail to function, in two very specific regions of the brain it is seen as vital for unpicking how Alzheimer's develops.

Dementia, of which Alzheimer's is the most common form, already affects 44 million people worldwide and that number is set to reach 135 million by 2050, according to Alzheimer's Disease International, a non-profit campaign group.

"Understanding how the healthy brain functions, especially areas of the brain crucial to learning and memory, is incredibly important in understanding what changes occur during conditions such as Alzheimer’s dis-

It is a decade since the last drug was approved to treat Alzheimer’s, and there is still no treatment that can slow the progression of the disease

ease," said Doug Brown, Director of research and development, Britain's Alzheimer's Society.

The Nobel Prize winners' work on the brain's navigation system stretches back more than 40 years, but more recently scientists have developed powerful new tools for studying brain circuits that O'Keefe plans to put to work at the new London research institute where his is director.

The first of more than 150 scientists will start work at the Sainsbury Wellcome Centre for Neural Circuits and Behaviour at University College London next year, using state-of-theart lasers, molecular biology and computational modeling to explore the brain's intricate wiring.

It is a decade since the last drug was approved to treat Alzheimer's, and there is still no treatment that can slow the progression of the disease, with current drugs only easing some of the symptoms of the disorder.

"We all know there is a time bomb there," O'Keefe said. "We are starting to get a handle on it but that doesn't mean it is going to turn into a cure in the immediate future."

Reuters

EXPRESS PHARMA

37

October 16-31, 2014

PHARMA ALLY VENDOR NEWS

IDTBiologika sets up new multipurpose biologics and vaccines facility The fully integrated facility in Dessau, Germany, utilises a sterile liquid filling line engineered to handle up to 24,000 vials per hour IDT BIOLOGIKA has completed and certified the construction of a large-scale production facility dedicated to filling and lyophilisation of biologics and vaccine products. The fully integrated facility in Dessau, Germany, utilises a sterile liquid filling line engineered to handle up to 24,000 vials per hour. Certified to biosafety levels (BSL) 1 and 2 for live vaccines, the facility has been designed and commissioned to be used for a range of advanced biomedical technologies required in medium to large clinical stage and commercial

stage volumes.

“Expanding our capabilities within a further multipurpose facility, IDT Biologika now offers one of the most dynamic facilities designed for biomedical products manufacture,” said Dr Ralf Pfirmann, Chief Executive Officer, IDT Biologika.

“Completion of this project, announced upon start of construction three years ago, allows us to accommodate production of an ever more diverse range of biomedical technologies with the precision and efficiency that comes with a highly integrated and auto-

The facility has been designed for a range of advanced biomedical technologies required in medium to large clinical stage

Anshul Life Sciences partnership with Mingtai moves to next level The new arrangement will help both Mingtai and Anshul Life Sciences to meet the requirements of the pharma customers in a better manner TAIWAN-BASED Mingtai Chemical Co, a leading global supplier of microcrystalline cellulose, (Comprecel grades), Croscarmellose Sodium (Disolcel) and Colloidal MCC (Neocel) has announced that Anshul Life Sciences will be their only authorised channel partner for India.

Anshul has been working with Mingtai as their channel partner for almost a decade.

This new arrangement will help both Mingtai and Anshul Life Sciences to meet the requirements of the pharma customers in a better manner. The application laboratory managed by

38 EXPRESS PHARMA October 16-31, 2014

Anshul Life Sciences will be the only authorised channel partner for India professionals at Anshul Life Sciences will help in providing solutions to customers in using Mingtai products.

Mingtai considers India as a strategic market for future

growth and Anshul Life Sciences, with their expertise and understanding of the excipient market, will be able to help Mingtai in their growth plans. Anshul Life Sciences is a leading supplier of excipients, specialty chemicals and advance intermediates for APIs to the pharma industry.

Anshul Life Sciences is an ISO 9001:2008 and 18001:2007 certified company, meeting unique needs of the pharma industry through innovative solutions and products offered from leading global manufacturers.

EP News Bureau - Mumbai

mated facility,” he added.

Included among the company’s specialised manufacturing capabilities are drug substance and drug product capabilities for live recombinant and non-recombinant vaccines and, in separate units, fill-and-finish capabilities for other biologics and small molecule drugs including cytotoxics. All biomedical products produced in the new multipurpose facility may be manufactured in the form of liquid or freeze-dried (lyophilised) presentations.

IDT Biologika’s vaccine development team are experts

in live viral vectors increasingly utilised in the development of novel vaccines. The new facility further supports these development capabilities. A fully automated loading and unloading freeze-dryer system now in place for live recombinant and non-recombinant products gives the company a leading manufacturing role in its area of expertise. A freezer-dryer shelf capacity of 40 sq mt, equal to a maximum 178,000 vials per batch, compliments its production system.

EP News Bureau-Mumbai

IKAlaunches mobile application laboratory van The van will start its journey from Bangalore and will cover 15 states IKA INDIA, a subsidiary of IKA group, has launched its first mobile application laboratory (MAL) van in India. The van will showcase the portfolio of IKA and is equipped with products like magnetic stirrers, overhead stirrers, shakers, thermostats, rotary evaporator, laboratory reactors and calorimetres. The MAL van will give live experience to customers for conducting the experiments with their samples.

The MAL van will be used to provide servicing of equipment to the existing customers by giving them

free service check ups. The journey of the MAL van will start from Bangalore and it will cover approximately 15 states. During this journey, the MAL van will visit customers from pharma, biotech, life sciences, R&D institutions, etc.

In addition, the MAL van will also visit academic institutions like pharmacy colleges, engineering schools, universities, etc and provide information to students about the scientific equipment of IKA. EP News Bureau - Mumbai

Signet ties-up with 3VSigma SPA Collaboration will provide a platform for Signet and 3V Sigma to target various pharma segments 3V SIGMA SPA, an Italybased multinational company, dynamic entity in chemical products and Signet Chemical Corporation have entered into a partnership for the versatile line of pharma grade Carbomers branded “Synthalen”.

This collaboration will provide a platform for Signet and 3V Sigma to target various pharma segments such as the solid dosage formulations (as controlled release application), buccal, intestinal, ophthalmic, nasal, vaginal and rectal formulations (as a bioadhesive) and oral suspensions as well as various topical preparations (as a thickening, suspending and gelling agent).

Commenting on this partnership, Claudio Carminati, Managing Director, 3V Sigma said, “3V Sigma is pleased to partner with Signet, which is an established Excipient distributor for nearly three decades. Signet is known for exceeding customer expectations by providing excellent technical and regulatory support in addition to sales, warehousing and distribution.

This is reason enough for us to place our trust and confidence in them.”

“We are delighted to team up with 3V Sigma, a company whose uniqueness is founded in its diversified line of chemical products including Carbomers and we look forward to a fruitful partnership with them,” said Harish Shah, Managing Director, Signet.

With over 55 years of experience in the chemical industry, 3V Sigma is positioned to meet all the challenges of the future. Over the years, with continuous innovations, a forward-looking vision for the business and strong technical know-how they have grown and carved a niche for themselves in the global market.

EP News Bureau - Mumbai

EXPRESS PHARMA

39

October 16-31, 2014

PHARMA ALLY PRODUCTS

Perlen Packaging launches PVdC-based blister films PERLEN PACKAGING has entered the ultra-high barrier segment with PVdC-based blister films and launched PERLALUX - Ultra protect with highest water vapour and oxygen barrier properties.

The Swiss company’s latest innovation has succeeded in doubling the moisture and oxygen barrier again, using a multi-layer PVdC technology.

The demands of the pharma industry on blister film barrier characteristics have increased substantially in recent years. The high barrier segment is growing at double digit percentages, driven by more complex molecular structures of new drugs, increased sales into tropical climate zones and the trend towards global distribution.

PERLALUX Ultra protect films provide high

comparison with PCTFE films, PERLALUX - Ultra protect impresses with its much higher oxygen barrier at equivalent moisture barrier and by its substantial cost advantages.

transparency and can be processed on all standard blister lines with the same parameters as standard PVdC

films, without the need of additional forming aids. The symmetrical structure can be sealed on both sides to the

aluminium lid foil. The barrier layers in the middle give optimum protection and highest product safety. In

Contact details Johannes Giessler Director Sales & Marketing Perlen Packaging Perlen Converting AG CH6035 Perlen / Switzerland Tel: +41 41 455 88 21 Mob: +41 79 685 333 9 Fax: +41 41 455 88 01 johannes.giessler@perlenpack aging.com www.perlenpackaging.com

Phenomenex expands Aeris peptide core-shell column line PHENOMENEX HAS added a 5 μm particle size to its family of Aeris PEPTIDE core-shell columns, enabling higher efficiencies and higher loading capability for small-scale peptide purification in 10 mm ID semi-prep columns and 21.2 mm ID AxiaTM-packed prep columns. Aeris PEPTIDE is fully scalable over four particle sizes – 1.7 μm, 2.6 μm, 3.6 μm, and 5 μm – enabling easy method transfer from analytical HPLC and UHPLC to preparative applications.

Aeris PEPTIDE is ideal for biomolecule separations in

40 EXPRESS PHARMA October 16-31, 2014

pharma and life science applications.

The Phenomenex Axia preparative format delivers longer column lifetime, higher efficiencies, improved performance and high reproducibility, compared to conventionally packed columns for lab-scale preparative chromatography.

Contact details Jennifer Dahlgren, Dahlgren Communications Phone: (530) 263-6817 E-mail: dahlgrenpr@comcast.net

Mix with the world of pharma, products, people & solutions

2-4 December 2014

Bombay Convention & Exhibition Centre Mumbai, India

Visitor Registration is Now Open Register online now and do business with 32,000 pharma professionals from all over the world @ CPhI & P-MEC India 2014!

ster i g e R ! now

Log on to: www.cphi.com/india/visit/register Benefits of Online Registration:

• Avail FREE entry to the exhibition on all the 3 days • Save Rs. 500 per person for onsite registration • Receive your personalized entry badge well in advance • Get fast track entry into the exhibition by avoiding long queues • Receive a free copy of the official show catalogue • Network and gain access to one of the world's fastest growing pharmaceutical markets

Co-located with:

In partnership with:

Supported by:

PHARMA ALLY

Bosch introduces CIP system specifically for use with human vaccines BOSCH PACKAGING Technology has launched a special version of a CIP (Cleaning in Place) system. The CIP system is manufactured by Pharmatec, a subsidiary of Bosch Packaging Technology.

The CIP system from Bosch is used for cleaning the pharmaceutical purification equipment, which ranges from the harvesting system to a variety of filtration and separation systems to the process tank with finished active substance concentrate, and at the same time thermally inactivates the wastewater.

The CIP system and all system modules are designed

according to biosafety level 3 (BSL 3). To keep viruses from escaping to the outside, Bosch has designed a completely closed system with fixed piping and a hermetic CIP pressure vessel.

The pumps for supply and return of rinsing media are equipped with double mechanical seals and sealing liquid (pure steam condensate) in the space between the seals, ensuring that no contaminated cleaning media escapes into the environment.

The system in compact skid design provides essential advantages to the user: Due to its modular construction, it can

be transported easily, as well as set up and connected to the media supply of the building quickly. If production is moved to another location, the system can be reinstalled at the new site without difficulty. The touch control panel with a user-

friendly menu enables simple parameterisation of the cleaning programme. All components and parts coming in contact with the media are made of stainless steel and fitted with a highquality surface. Hence the system can clean itself without residue between applications, and can be sanitised with water for injection (WFI) at a temperature of 125 degrees celsius. As a satellite system, the CIP system is designed for cleaning of various process systems on a rotating basis, as well as for cleaning of tubing or loops. With a volume of 800 litres, the CIP tank has the necessary size to clean process

tanks with a useable volume of approximately 2000 litres.

Sodium hydroxide, which is prepared in a separate tank, is used as the cleaning medium.

Contact details Robert Bosch GmbH Postfach 10 60 50 D-70049 Stuttgart E-mail christin.poenisch@bosch.com Phone +49 711 811-58502 Fax +49 711 811-58509 Corporate Communications, Brand Management, and Sustainability Senior Vice President: Uta-Micaela Dürig www.bosch-press.com

TO ADVERTISE IN EXPRESS PHARMA, CONTACT: 2nd Floor, Whites Road, Royapettah, Chennai- 600 014 Board Line: 044- 28543031/2/3 044- 42285522 Mobile: +91 9710022999 Fax: 044- 28543035 Email id: yuvaraj.murali@expressindia.com HEAD OFFICE MUMBAI Rajesh Bhatkal The Indian Express Ltd Business Publication Division 2nd Floor, Express Tower, Nariman Point, Mumbai- 400 021 Board line: 022- 67440000 Ext. 527 Mobile: +91 9821313017 Email Id: rajesh.bhatkal@expressindia.com

BANGALORE G.M. Khaja Ali The Indian Express Ltd Business Publication Division 502, 5th Floor, Devatha Plaza, Residency road, Bangalore- 560025 Board line: 080- 49681100 Ext. 108 Mobile: +91 9741100008 Fax: 080- 22231925 Email id: khaja.ali@expressindia.com

BRANCH OFFICES NEW DELHI Ambuj Kumar The Indian Express Ltd Business Publication Division Express Building, 9&10, Bahadur Shah Zafar Marg, New Delhi- 110 002 Board line: 011-23702100 Ext. 668 Mobile: +91 9999070900 Fax: 011-23702141 Email id: ambuj.kumar@expressindia.com

HYDERABAD E.Mujahid The Indian Express Ltd Business Publication Division 6-3-885/7/B, Ground Floor, VV Mansion, Somaji Guda, Hyderabad – 500 082 Board line- 040- 66631457/ 23418673 Mobile: +91 9849039936 Fax: 040 23418675 Email Id: e.mujahid@expressindia.com

CHENNAI Yuvaraj Murali The Indian Express Ltd Business Publication Division New No. 37/C (Old No. 16/C)

KOLKATTA Ajanta Sengupta The Indian Express Ltd Business Publication Division JL No. 29&30, NH-6, Mouza- Prasastha & Ankurhati,

42 EXPRESS PHARMA October 16-31, 2014

Vill & PO- Ankurhati P.S.- Domjur (Nr. Ankurhati Check Bus Stop) Dist. Howrah- 711 409 Mobile: +91 9831182580 Email id: ajanta.sengupta@expressindia.com KOCHI Yuvaraj Murali The Indian Express Ltd Ground Floor, Sankoorikal Building, Kaloor – Kadavanthra Road Kaloor, Kochi – 682 017 Mobile: +91 9710022999 Email id: yuvaraj.murali@expressindia.com COIMBATORE G.M. Khaja Ali The Indian Express Ltd No. 205-B, 2nd Floor, Vivekanand Road, Opp. Rajarathinam Hospital Ram Nagar Coimbatore- 641 009 Mobile: +91 9741100008 Email id: khaja.ali@expressindia.com

AHMEDABAD Rajesh Bhatkal The Indian Express Ltd 3rd Floor, Sambhav House, Near Judges Bunglows, Bodakdev, Ahmedabad - 380 015 Mobile: +91 9821313017 Email Id: rajesh.bhatkal@expressindia.com BHOPAL Ambuj Kumar The Indian Express Ltd F-102, Inner Court Apartment, 1st Floor, GTB Complex, Behind 45 Bungalows, Bhopal - 462 003 Mobile: +91 9999070900 Email id: ambuj.kumar@expressindia.com JAIPUR Ambuj Kumar The Indian Express Ltd S2, J-40, Shyam GHP Enclave, Krishna Marg, C-Scheme, Jaipur - 302 001 Mobile: +91 9999070900 Email id: ambuj.kumar@expressindia.com

IMPORTANT Whilst care is taken prior to acceptance of advertising copy, it is not possible to verify its contents. The Indian Express Limited. cannot be held responsible for such contents, nor for any loss or damages incurred as a result of transactions with companies, associations or individuals advertising in its newspapers or publications. We therefore recommend that readers make necessary inquiries before sending any monies or entering into any agreements with advertisers or otherwise acting on an advertisement in any manner whatsoever.

BUSINESS AVENUES

EXPRESS PHARMA

EXPRESS PHARMA

October 16-31, 2014 43

BUSINESS AVENUES

EXPRESS PHARMA

We care for your family . . .

Anti-Inflammatory Enzymes Serratiopeptidase Peptizyme (enteric coated serratiopeptidase granules) Trypsin Chymotrypsin mix ( 6:1)

Probiotics Saccharomyces boulardii Lactic acid basillus sporogenous

Circulatory Health Nattokinase

Bio Catalysts Immobilized Cal B

Digestive Aids Alpha amylase / fungal diastase / fungal amylase Alpha galactosidase Bacterial alpha amylase Bromelain Hemicellulase Lactase Lipase Ox bile

Papain Pepsin Pancreatin Protease ( acid / alkali)

Advanced Enzyme Technologies Limited Sun Magnetica, 'A' wing, 5th Floor, Accolade Galaxy, LIC Service Road, Louiswadi, Thane(W) - 400604, India Tel: +91 22 41703200, Fax: +91 22 25835159 • E-mail : info@enzymeindia.com • Website: www.enzymeindia.com

44

October 16-31, 2014

Non-GMO ISO CERTIFICATION

GOTS CERTIFICATION

Products

WHO cGMP

FDA

EXPRESS PHARMA

BUSINESS AVENUES Express Pharma AD_25Aug.ai

EXPRESS PHARMA

1

01/09/14

5:13 PM

EXPRESS PHARMA

October 16-31, 2014 45

BUSINESS AVENUES

46

October 16-31, 2014

EXPRESS PHARMA

EXPRESS PHARMA

BUSINESS AVENUES

EXPRESS PHARMA

EXPRESS PHARMA

October 16-31, 2014 47

BUSINESS AVENUES

48

October 16-31, 2014

EXPRESS PHARMA

EXPRESS PHARMA

BUSINESS AVENUES

EXPRESS PHARMA

EXPRESS PHARMA

October 16-31, 2014 49

BUSINESS AVENUES

EXPRESS PHARMA

6,/,&21(6 Peroxide Cured

Braided

Platinum Cured

Ring

Tri Clover

Septa

Washer

Cork

Gripper

Flush Bottom

Profile

Butterfly

86 )'$ UHJXODWLRQV &)5 IRU FRQWDFW ZLWK IRRG 863 FODVV 9, UHTXLUHPHQWV (XURSHDQ 3KDUPDFRSRHLD $QLPDO GHULYDWLYH IUHH

DMF No. 26710 Certified Cleanroom

205 & 206 Hill View Industrial Premises, Amrut Nagar, Ghatkopar (W), Mumbai - 400 086, India.

Tel.#:022-2500 4576 Fax #:022-2847 5722 E-mail :sales@mksilicone.com

50

October 16-31, 2014

Blue Heaven

M. K. Silicone Products Pvt. Ltd.

EXPRESS PHARMA

BUSINESS AVENUES

EXPRESS PHARMA

film coating Is your

as

good

?

as you think it is

LYCOAT

速

for quicker quality coating.

Roquette LYCOAT 速 is a major breakthrough in aqueous film coating. Dramatically reduced coating times deliver important cost savings. Lump - and foam-free suspensions come easily.

And excellent mechanical properties, high gloss and true smoothness without logo bridging guarantee unbeatable quality, every time.

Thinking film coating ?

Think LYCOAT 速

ROQUETTE, through its production units (in Europe, in Asia and in the United States) and its international distribution network, will assure a constant quality of products and services throughout the whole world.

www.roquettepharma.com For your local contact : Roquette India Pvt Ltd Email : pharmabiz.india@roquette.com - Tel : +91 22 2570 6775 Our local Distributor : Signet Chemical Corp. Pvt Ltd - Email : sales@signetchem.com EXPRESS PHARMA

October 16-31, 2014 51

BUSINESS AVENUES

EXPRESS PHARMA

AVAILABLE DIRECTLY FROM THE MANUFACTURER AT HIGHLY COMPETITIVE PRICES < Ortho / Para Anisic Acid < Ortho / Para Cyano Phenol < 2 – Ethoxy Benzoic Acid < 1 / 6 – Hydroxy – 2 – Napthoic Acid < 3 / 4 / 5 – Methyl Salicylic Acid & Ester < 3 / 4 / 5 – Chloro Salicylic Acid < 3 / 4 / 5 – Amino Salicylic Acid < 6 – Methoxy – Naphthaldehyde < All types of Paraben & Mixtures thereof.

AN ISO 9001 : 2008 & 14001: 2004 COMPANY OUR PRODUCTS ARE STAR K-KOSHER & HALAL CERTIFIED

3A, Barodawala Mansion, 81, Dr. A.B. Road, Worli, Mumbai-400018.

Tel : +91-22- 43625500 Fax : +91-22-24974886 E-Mail : gujorg@gujaratorganics.com Web : www.gujaratorganics.com

52

October 16-31, 2014

EXPRESS PHARMA

BUSINESS AVENUES

EXPRESS PHARMA

2

Designers, Engineers & Manufacturers of Machinery & Filteration Equipments for:

es Decad ies. ustr Over d In to ice of serv ing Stronger Grow t & Integrity us with Tr

Pharmaceuticals, Packaging, Chemicals, Food, Beverages, Distilleries, Breweries, Paints, Food, Oils & Consumers

MAJOR PRODUCTS MANUFACTURED AT UNIPACK Linear Vial/Bottle Washing Machines Sizes: vials 2ml to 100 ml & Bottles 15 ml to 500 ml Scramblers/Unscramblers Sizes:24” dia, 36” dia. 48” dia 60” dia Hydraulic Loading Platforms Inspection Tables Loading and unloading Conveyors Liquid Filling, Rubber Stoppering & aluminium Cap sealing Machines for Vials Powder Filling, Rubber Stoppering & aluminium Cap sealing Machines for Vials

Sterlity Testing Units in S.S. Sizes: Single Place, Three Place & Six Place Plate and Frame Type Filter press in SS Size: 20 cm X 20 cm, 40 cm X 40 cm, 60 cm X 60 cm, 100 cm X 100 cm Zero hold up/Sparkler Filter press Size : 600 LPH to 15500 LPH Sterile Pressure and Storage Vessels Size : 10 ltrs to 500 ltrs Membrabe Filter Holders (Size: 293 mm, 142mm, 90mm) Inline Filter Holders (Size:47mm, 25mm, 13mm) Basket/Bag/Catridges Filters

We Supply different sizes of Filter Sheets and Filter Modules of Major International Brands

Our Achievements: Over 2500 installations of our major products manufactured in-house are supplied to all Leading Companies in India & Multinationals abroad

EXPRESS PHARMA

October 16-31, 2014 53

BUSINESS AVENUES

EXPRESS PHARMA

TABLET GRINDER RM 200 Two great brands come together under Charles River to provide an even stronger testing solution for our customers.

If you are looking for a grinder for reliabe and reproducible sample preparation of pharmaceutical materials, look no further than RETSCH.

Microbial Detection & Identification

n Mixing and homogenization of powders and pastes n Gentle grinding down to <10 microns, dry and wet n Ideal for the preparation of homeopathic medicine n Cryogenic grinding of frozen yeast cells (â&#x20AC;&#x2DC;noodlesâ&#x20AC;&#x2122;) possible

Charles River Laboratories India Private Limited Bangalore (Regd. Office): Phone: 080 25588175 / 76 / 77. Email: blroffice@crl.com Ahmedabad: Phone: 079 40194730. Email: ahdoffice@crl.com Hyderabad: Phone: 040 27179998. Email: hydoffice@crl.com Mumbai: Phone: 022 27810061. Email: bbyoffice@crl.com Mumbai - Accugenix Facility: Phone: 022 41270504 / 05 / 08. Email: CRLIaccugenix@crl.com

www.criverindia.com

n Mortars and pestles in 7 different materials n Easy to use and clean

www.retsch.com

54

October 16-31, 2014

EXPRESS PHARMA

BUSINESS AVENUES

EXPRESS PHARMA

EXPRESS PHARMA

October 16-31, 2014 55

BUSINESS AVENUES

56

October 16-31, 2014

EXPRESS PHARMA

EXPRESS PHARMA

BUSINESS AVENUES

EXPRESS PHARMA

EXPRESS PHARMA

October 16-31, 2014 57

BUSINESS AVENUES

EXPRESS PHARMA

Leaders in Cleanroom Lighting

customised

500 + variants installations 2000 + across India

years... and still going strong

Latest in lighting technology for your Cleanrooms Energy efficient LED lighting now offered for Cleanrooms

visionLED

Business Office: Wipro Lighting, 5 floor, Godrej Eternia - C, Old Pune-Mumbai road, Shivajinagar, Pune - 411 005 helpdesk.lighting@wipro.com | Tel : 020-66098700 | Fax : 020-66098777 | www.wiprolighting.com Branch Offices:

New Delhi : 011-41708122-29/ 9971117364 | Hyderabad : 040-27176082/ 27178906 / 05 | Mumbai (Vikhroli): 022-67213755 | Pune : 020-25510583 / 25535081 | Chandigarh : 0172-5018734 / 2660714 | Bangalore: 080-41503260-68 | Chennai : 044-32518016 | Ahmedabad : 079-40073546 | Kolkata : 033-44045886

Life- Care

www.life-care.co.in 58

October 16-31, 2014

EXPRESS PHARMA

BUSINESS AVENUES

EXPRESS PHARMA

EXPRESS PHARMA

October 16-31, 2014 59

BUSINESS AVENUES

60

October 16-31, 2014

EXPRESS PHARMA

EXPRESS PHARMA

BUSINESS AVENUES

EXPRESS PHARMA

EXPRESS PHARMA

October 16-31, 2014 61

BUSINESS AVENUES

EXPRESS PHARMA

Technology that’s Instrumental In Your Success MOLECULAR WEIGHT MOLECULAR SIZE MOLECULAR STRUCTURE PARTICLE SHAPE PARTICLE SIZE SOLUTION VISCOSITY RHEOLOGICAL PROPERTIES ZETA POTENTIAL CHEMICAL IDENTIFICATION

62

October 16-31, 2014

EXPRESS PHARMA

BUSINESS AVENUES

EXPRESS PHARMA

EXPRESS PHARMA

October 16-31, 2014 63

BUSINESS AVENUES

EXPRESS PHARMA

Trade-IN / Buy-Back Offer!

Head Only Price 1,10,000/-* # Only

DV-E Viscometer our lowest cost digital viscometer

Features and Benefits Ø No calculations required - Direct reading of viscosity in cP or mPa•s Ø Displayed Info: - Viscosity (cP or mPa•s) - % Torque - Speed/Spindle Ø Easy-to-Use: - Flip a switch - Turn the knob Ø Spindle/Speed Selection Ø Flip to “Speed” - Turn the knob - Choose RPM Ø Flip to “Spindle” - Turn the knob - Choose spindle Ø Auto Range push for determining full scale range (FSR) viscosity Ø 18 Speeds for complete range capability Ø Accuracy: ±1.0% of range Ø Repeatability: ±0.2%

BRK INSTRUMENTS LLP. ANM House, Plot No. A-141, Road No. 23, Wagle Industrial Area, Thane (W) 400 604. INDIA

Tel.: Fax: Email: URL:

91-22 - 6614 1666 91-22 - 6614 1678 info@brkindia.net www.brkindia.net

VISCOSITY RANGE cP(mPa•S) MODEL

Min.

Max.

SPEEDS RPM

Number of increments

LVDV-E

1†

2M

.3-100

18

RVDV-E

100††

13M

.3-100

18

HADV-E

200††

26M

.3-100

18

HBDV-E

800††

104M

.3-100

18

† 1 cP achieved with UL Adapter accessory. 15 cP on LV with standard spindles. †† Minimum viscosity is achieved with optional RV/HA/HB-1 spindle.

M = 1 million cP = Centipoise mPa•s = Millipascal•seconds

Offer valid till 31st Dec,. 2014 * 1) Trade-in/buy-back offer, exchange with any Brookfield viscometer Head only against New Brookfield DV-E viscometer Head only. .

2) New DV-E supplied with Main Head, Guard Leg (LV/RV only) Calibration Certificate, Carrying Case (CPS fluids not included).

3) Use Existing Spindle Set and Viscometer Stand. # VAT / Taxes extra as applicable.

www.brookfieldengineering.com 64

October 16-31, 2014

EXPRESS PHARMA

BUSINESS AVENUES

EXPRESS PHARMA

EXPRESS PHARMA

October 16-31, 2014 65

BUSINESS AVENUES

EXPRESS PHARMA

A Great Tool for Oral Solid Dosage Challenges

FT4 Powder Characterisation System • 7 Different Tests to characterize Powders • Controls Tablet Variation • Flowability • Bulk Density • Shear Cell • Aeration • Blend Uniformity • End point Wet Granulation & many more

e d uc ss e R oce Pr ost C

For further information, please contact us:

E-mail: delhi@aimil.com

Tel: 91-11-3081 0244

www.aimil.com

Offices at : • Delhi (H.O.) • Mumbai • Bengaluru • Kolkata • Chennai • Vadodara • Hyderabad • Chandigarh • Guwahati • Bhubaneswar • Indore • Lucknow • Kochi

66

October 16-31, 2014

Aimil/Ad/A&I/14-15/10/24

Freeman Technology Ltd., U.K.

EXPRESS PHARMA

BUSINESS AVENUES

EXPRESS PHARMA

EXPRESS PHARMA

October 16-31, 2014 67

PHARMA LIFE AWARD

Glenmark bags Civic Award 2013-14 Bombay Chamber of Commerce and Industry presents the award for exemplary initiatives in the area of CSR GLENMARK PHARMACEUTICALS has won the Civic Award 2013-14 for Social Development by the Bombay Chamber of Commerce and Industry (BCCI). The accolade was presented to Glenmark for its exemplary initiatives in the area of Corporate Social Responsibility (CSR) through which the company has positively impacted over 600,000 lives till date.

The award was received by Cheryl Pinto, Director Corporate Affairs - Glenmark in Mum-

bai recently. The Bombay Chambers Civic Awards was instituted in 1984 with an objective of promoting good corporate citizenship and rewarding and recognising the best practices in CSR. Pinto said, “The award is a testament to our continued commitment of enriching lives and making a positive difference in the communities in which we operate. It acknowledges Glenmark’ s contribution in impacting over 600,000 lives through

our initiatives in child health, sustainable livelihood, providing access to healthcare through medicine donation and global employee volunteering programmes.”

Thanking the company’s employees and NGO partners for their unstinted support and dedication, she added, “I am sure this recognition by a leading industry body will provide us the impetus to pursue our mission of enriching lives with renewed vigour."

Cheryl Pinto, Director Corporate Affairs - Glenmark receives the award

Instituted with the mission of ‘Enriching Lives’; Glenmark Foundation, the CSR arm has been implementing several projects for the benefit of the less privileged sections of the society

under three core areas: child health (flagship programme), sustainable livelihoods and employee volunteering.

EP News Bureau-Mumbai

CAMPUS BEAT

HK College of Pharmacy celebrates 6th Scientific Day One day seminar and celebration of TechCrunch 2014 were part of the event HK COLLEGE of Pharmacy’s, HK Knowledge Base, recently celebrated its 6th Scientific Day, TechCrunch 2014 on the Occasion of World Pharmacist Day. The two-day event had a seminar on ‘Frontiers in Pharmaceutical Sciences and Drug Discovery Innovations' along with poster competitions. Both the days were open for participation to all pharmacy and science colleges. Students of colleges across Mumbai, Navi Mumbai, Kalyan, Nasik, Satara and Gulbarga participated in the seminar.

Scientific Day included competitions like model making (18 groups), pharma quiz (14 groups), oral presentation (eight groups), innovative product packaging (six groups), pharma treasure hunt (nine groups), pharma debate (eight groups).

Students from Narsee Monjee Institute of Management Studies (NMIMS)-Vile Parle, MET

68 EXPRESS PHARMA October 16-31, 2014

Dr Hitesh Doshi, Managing Director, Indeus life Sciences giving the keynote address

College of Pharmacy- Bandra, K M Kundanani College of Pharmacy-Colaba, Dr LH Hiranandani College of Pharmacy- Ulhasnagar and Viva College of Pharmacy- Virar, Oriental College of Pharmacy-Sanpada also participated n the seminar Dr Hitesh Doshi, Managing Director, Indeus Life Sciences was the chief guest. The day proceeded with the sessions on ‘Lipid Nanocarriers: Trojan

horse for Intracellular Delivery’

by Dr Vandana Patrawale, Prof of Pharmaceutics, ICT, Mumbai, ‘Pharmacological Aspects of Herbal Drugs and Modern Medicines’ by Nitin Mahurkar, Prof and HOD Pharmacology, Prof in Charge Pharm D, Matoshree Taradevi Rampure Institute of Pharmaceutical Sciences, Gulbarga, ‘Molecular modelling in drug design and development’

by Dr Evans Coutinho, Prof and

HOD of Pharm Chemistry, BCP, Mumbai, ‘Herbal-based Cosmoceuticals’ by Renuka Thergaokar, Chief Executive Officer, ALCOS International.

A total of 53 posters were presented for the competition from different categories of pharmacy field. The evaluation of posters were done in two rounds.

HK College of Pharmacy-Jogeshwari, ICT- Matunga Mumbai, Vivekanand Education Society’s College of Pharmacy, Chembur Mumbai, Dr LH Hiranandani College of Pharmacy, Ulhasnagar, Sandip Foundations, Sandip Institute of Pharmacy-Nasik, Saraswati Vidya Bhavan’s College of PharmacyDombivali, Shri DD College of Pharmacy-Panvel, Rajiv Gandhi College of Pharmacy- Gulbarga Karnataka, Sahyadri College of Pharmacy- Sangola, PSGVP Mandal’s Institute of Pharmacy,

Shahada Nandurbar took part in the poster presentation.

ICT students bagged the first prize for ‘Curcumin: A novel phytochemical alternative for alpha synuclein induced Parkinson’s Disease’, the second prize went to Vivekanand Education Society’s College of PharmacyChembur Mumbai for ‘Green Chemistry for a sustainable future’ and the third prize went to HK College of Pharmacy for ‘PsychopharmacolgyParasomnia’.

The consolation prize were bagged by HK College of Pharmacy for preparation and evaluation of polyherbal formulation for its wound healing activity', HK College of Pharmacy for development and evaluation of lafutidine solid dispersion via hot melt extrusion: investigating drug-polymer miscibility with advanced characterisation.

EP News Bureau-Mumbai

Amersham* Western Blot System The new standard in western blotting designed to deliver consistent, quantifiable data every sample, every time Amersham Western Blotting is a fully integrated system for SDS-PAGE and Western blotting of proteins based on fluorescence detection. This system minimizes assay variability to provide you with quantifiable data, every sample, every time.

Benefits Reproducibility, across experiments and operators • Fully integrated system • Dedicated consumables • Optimized reagents • Optimized protocols • Automated data analysis Quantitative • Total protein in normalization • Fluorescent multiplexing • Integrated laser scanner

www.gelifesciences.com/artofwesternblotting For more details contact your local GE sales representative or write to supportdesk.india@ge.com

GE and GE monograms are trademarks of General Electric Company. *Amersham, Biacore, Äkta, Whatman, Cytell and Xuri are trademarks of General Electric Company or one of its subsidiaries. ©2014 – General Electric Company. All rights reserved.

REGD.WITH RNI NO.MAHENG/2005/21398 REGD.NO.MH/MR/SOUTH-77/2013-15, PUBLISHED ON 5TH & 20TH EVERY FORTNIGHLY & POSTED 6-7-8 & 21-22-23 OF EVERY FORTNIGHLY. POSTED AT MUMBAI PATRIKA CHANNEL SORTING OFFICE.